

26 ¹¹Present address: Center for Substance Abuse Research, Lewis Katz School of Medicine,
27 Temple University, Philadelphia, PA 19140, USA and Department of Neural Sciences, Lewis Katz
28 School of Medicine, Temple University, Philadelphia, PA 19140, USA

29

30 *Correspondence to:

31 Alexandra L. Joyner

32 Developmental Biology Program

33 Sloan Kettering Institute

34 1275 York Avenue, Box 511

35 New York, NY 10065, USA

36 Office: 212-639-3962

37 Email: joynera@mskcc.org

38 **Abstract**

39 The capacity of the brain to compensate for insults during development depends on the type of
40 cell loss, whereas the consequences of genetic mutations in the same neurons are difficult to
41 predict. We reveal powerful compensation from outside the cerebellum when the excitatory
42 cerebellar output neurons are ablated embryonically and demonstrate that the minimum
43 requirement for these neurons is for motor coordination and not learning and social behaviors. In
44 contrast, loss of the homeobox transcription factors *Engrailed1/2* (*EN1/2*) in the cerebellar
45 excitatory lineage leads to additional deficits in adult learning and spatial working memory, despite
46 half of the excitatory output neurons being intact. Diffusion MRI indicates increased thalamo-
47 cortico-striatal connectivity in *En1/2* mutants, showing that the remaining excitatory neurons
48 lacking *En1/2* exert adverse effects on extracerebellar circuits regulating motor learning and
49 select non-motor behaviors. Thus, an absence of cerebellar output neurons is less disruptive than
50 having cerebellar genetic mutations.

51 **Introduction**

52 The brain has a large capacity to compensate for neuronal loss due to injury when it occurs during
53 development but not in adulthood. In contrast, germline mutations in genes that regulate neural
54 development that result in hypoplasia can have deficits that range from minor to devastating. It is
55 particularly important to understand the causes of behavior deficits in the context of pediatric
56 cerebellar defects, as the degree of recovery of cerebellar function seems to be differentially
57 influenced by the location and extent of insult or the type of genetic mutation^{1,2,3,4,5}. As the
58 cerebellum is a complex folded structure housing the majority of the neurons in the brain^{6,7} and
59 many lobules in the cerebellum share functions with another lobule that converges onto similar
60 downstream forebrain targets⁸, the cerebellum is an important structure to study developmental
61 compensation.

62 The communication between the cerebellum and the rest of the brain is through the
63 downstream cerebellar nuclei (CN) and they contribute to a wide range of motor and non-motor
64 functions^{9,10,11,12}. The CN comprise three bilaterally symmetrical nuclei and form a topographic
65 circuit between their presynaptic Purkinje cells (PCs) based on their spatial position within lobules
66 and along the mediolateral axis of the cerebellar cortex^{13,14,15,16,17,18,19}. The circuit functions of
67 subregions of the CN have begun to be defined in adult animals by mapping their projections and
68 transiently inhibiting neural activity using targeted viral injections or neuronal ablation^{9,10,11,12}. In
69 addition, many studies have manipulated specific lobules in the cerebellar cortex and inferred
70 which CN are involved in regulating motor coordination, motor learning and/or non-motor
71 behaviors based on circuit topography. An additional consideration for ablation studies is that
72 during development, the excitatory neurons of the CN (eCN) play a pivotal role in supporting the
73 survival of PCs which in turn ensure the proper expansion of other cell types in the cerebellar
74 cortex through secretion of Sonic hedgehog^{18,20,21}. Thus, growth of each lobule is dependent on

75 the eCN targets of their PCs, and removing a subset of eCN embryonically will impact the
76 development of both their downstream forebrain targets and presynaptic PCs and their local
77 microcircuit. Given the crucial role eCN play in generation and circuit function of the cerebellum,
78 it is important to develop tools to enable manipulations of the same eCN during development and
79 in the adult to define the cerebellar-associated behaviors dependent on the neurons and uncover
80 possible developmental compensation.

81 We used the medial eCN as a test case for comparing the necessity of a CN subregion
82 during development versus in adulthood. We then determined the baseline requirement for having
83 all eCN intact during development and compare the behavior deficits to mouse mutants lacking
84 developmental genes in the eCN. We identified a *Cre* transgene that targets the medial eCN from
85 embryogenesis onwards. Using this tool we demonstrate that while in adult mice medial eCN
86 activity is required for reversal learning, the brain can compensate for embryonic loss of these
87 neurons alleviating the behavioral deficit. Surprisingly, we find that when all eCN are killed in the
88 embryo there is only a selective impairment in motor coordination behaviors. In contrast, genetic
89 loss of the engrailed (*EN1/2*) developmental transcription factors in all eCN results in additional
90 deficits in motor learning, acquisition/reversal learning, and spatial working memory, despite only
91 half the eCN dying embryonically. Circuit mapping and diffusion MRI (dMRI) provide evidence for
92 aberrant thalamo-cortical-striatal connectivity as a result of aberrant eCN development.

93

94 **Results**

95 ***SepW1-Cre* targets the excitatory neurons in the medial cerebellar nucleus**

96 We chose the medial CN as a region to compare adult inhibition and embryonic ablation of a CN
97 subregion as it can be divided into 4-5 subregions based on transcriptomic profiling and circuit
98 mapping^{14,22}. We screened transgenic databases (Gene Expression Nervous System Atlas and

99 Allen Brain Atlas Transgenic Characterization) for a *Cre* driver that within the CN selectively
100 targets the medial eCN. *SepW1-Cre*, a Selenow BAC construct²³, was found to mediate *Cre*
101 recombination only in the medial eCN. Immunostaining of cerebellar sections from *SepW1-Cre*
102 mice carrying a *Cre*-dependent nuclear tdTomato reporter²⁴ (*SepW1-Cre; Ai75D*) revealed that
103 within the eCN 92.6% of all tdTomato+ cells are in the medial CN (**Fig. 1a-f**). Moreover, within the
104 medial CN, 100% of tdTomato+ neurons expressed the eCN marker MEIS2+, and 8% of MEIS2+
105 neurons were not tdTomato+ (**Fig. 1f**). Approximately 50% of NeuN+ GCs in the internal granule
106 cell layer (IGL) also expressed tdTomato (**Supplementary Fig. 1a,b**), as well as all TBR2+
107 unipolar brush cells (UBCs) (**Supplementary Fig. 1a,c** and ref²⁵). Outside the cerebellum,
108 tdTomato+ labeling was restricted to the vestibular nucleus, cerebral cortex, hippocampus, a
109 subpopulation of hypothalamic nuclei and the nucleus of Darkschewitsch (see also Allen Brain
110 Atlas Experiment ID: 488246361). Thus, among the CN neurons, the *SepW1-Cre* transgene
111 selectively labels the eCN of the medial CN. Importantly, *Cre* is expressed in adult medial eCN,
112 allowing targeting of subpopulations of the neurons in adult mice using viral injections (see below).

113

114 **Acute inhibition of the adult posterior medial eCN impairs reversal learning and not motor** 115 **behaviors**

116 Leveraging *SepW1-Cre* mice, we tested the contribution of the posterior region of the medial eCN
117 (MedP eCN) to adult cerebellar-associated motor coordination, learning and non-motor behaviors.
118 Projections to the MedP CN^{14,18,26} that are preferentially from vermis lobules 6-8 have been shown
119 to contribute to cognitive flexibility, anxiolytic and stereotyped/repetitive behaviors^{16,27,28}, whereas
120 projections to the anterior medial CN (MedA), which originate from lobules 1-5^{17,18}, are associated
121 with motor functions^{17,29}. We therefore tested whether acute chemogenetic inhibition of the adult
122 MedP eCN would impair cognitive flexibility without affecting motor functions. A *Cre*-dependent
123 inhibitory (hM4Di) Gi-DREADD (*AAV2-hSyn-DIO-hM4Di-mCherry*; MedP-hM4Di mice) or control
124 vector (*AAV2-hSyn-DIO-mCherry*; Control mice) was injected bilaterally into the MedP CN of

125 *SepW1-Cre/+* littermates of both sexes (**Fig. 1g**). mCherry and hM4Di-mCherry expression was
126 confirmed to be limited to the MedP (**Fig. 1i** and **Supplementary Fig. 2a,b**) and we observed the
127 expected mCherry+ axon terminals in downstream motor and non-motor thalamic nuclei including
128 mediodorsal (MD), centrolateral (CL), ventromedial (VM) and parafascicular (PF) thalamus (**Fig.**
129 **1h**).

130 The MedP eCN were acutely inhibited during a battery of motor and non-motor behaviors
131 by injecting clozapine N-oxide (CNO, 5 mg/kg) 30 minutes before each behavioral test (**Fig. 1j**).
132 Motor coordination and balance were tested using the footprint assay and revealed no differences
133 in MedP-hM4Di mice compared to littermate controls injected with CNO (**Fig. 1k**). The open field
134 assay also showed no differences in total distance travelled (**Fig. 1l** and **Supplementary Fig. 2c**)
135 and average velocity (**Supplementary Fig. 2d**). Motor performance and learning using an
136 accelerating rotarod test and forelimb grip strength also revealed no differences (**Fig. 1m,n** and
137 **Supplementary Fig. 2e**). In contrast, when we tested acquisition and reversal learning as a
138 readout of cognitive flexibility using a water Y-maze (WYM) test, we found that MedP-hM4Di mice
139 showed normal acquisition learning for finding the submerged escape platform location, but had
140 significantly impaired reversal learning for a new platform location compared to controls (**Fig. 1o**).
141 As a test for spatial working memory, spontaneous alternations in a Y-maze revealed no
142 differences between groups (**Fig. 1p**). Although the MedP-hM4Di mice showed lower total
143 distance travelled (**Supplementary Fig. 2f**) in the Y-maze after CNO administration, the total
144 number of entries (**Supplementary Fig. 2g**) were comparable to control mice. Altogether, these
145 results demonstrated that acute inhibition of the MedP eCN in adult mice selectively impairs
146 reversal learning without having a major effect on motor functions.

147

148 **Generation of mice lacking the MedP eCN by conditional knockout of *En1/2***

149 To examine the impact of embryonic loss of MedP eCN on reversal learning we deleted *En1/2* in
150 the medial eCN using *SepW1-Cre* which initiates recombination at embryonic day 14.5 (E14.5;

151 **Supplementary Fig. 3a-d**), since deletion of *En1/2* in all eCN leads to preferential death of the
152 MedP and posterior interposed (IntP) eCN after E14.5¹⁸. We confirmed that 7-week-old *SepW1-*
153 *En1/2* CKO mice of both sexes (*SepW1-Cre; En1^{flox/flox}; En2^{flox/flox}*) have a loss of medial eCN by
154 quantifying large NeuN (100-600 μm^2) neurons as a proxy for eCN¹⁸. As predicted, there was a
155 preferential loss of eCN in the posterior medial CN, with little loss in the interposed and lateral CN
156 compared to littermate control mice (*En1^{flox/flox}; En2^{flox/flox}*)(**Fig. 2a,b**). As recently show, the loss
157 of medial eCN (MEIS2+ cells) was observed by E17.5 and primarily in the MedP region²⁵. This
158 was confirmed in 7-week-old *SepW1-Cre; Ai75D* and *SepW1-En1/2 CKO; Ai75D* mice, with
159 complete loss of tdTomato+ MedP eCN and approximately half of the tdTomato+ MedA eCN
160 remaining in the mutants (**Supplementary Fig. 3e**). The CN interneurons were also lost in the
161 MedP region as the only NeuN+ cells remaining in the region were displaced mutant UBCs
162 (**Supplementary Fig. 3e** and ref²⁵).

163 Given that the eCN support the survival of their presynaptic Purkinje cells (PCs), which in
164 turn support production of GCs and interneurons¹⁸, we confirmed that growth of the cerebellum
165 was reduced in the vermis of 6-week-old animals with proportional scaling down of GCs and
166 interneurons to PCs. There was a significant reduction in the vermis (20.3%) and paravermis
167 (10.1%) sagittal area, but not the hemispheres of *SepW1-En1/2* CKOs compared to littermate
168 controls (**Fig. 2c,d**). In addition, the areas of the molecular layer (ML) and the IGL was primarily
169 reduced in the vermis and their proportions were conserved relative to the total cerebellar area in
170 mutants (**Fig. 2e,f**). The density of Calbindin+ PCs, parvalbumin+ molecular layer interneurons
171 and NeuN+ GCs were also normal throughout the cerebellum (**Fig. 2g-l**). Thus, loss of MedP eCN
172 leads to a preferential reduction of growth in the vermis maintaining the proportions of neurons.

173

174 **Mice lacking MedP eCN have normal reversal learning as well as motor behaviors**

175 We next evaluated *SepW1-En1/2* CKOs and their littermate controls of both sexes in the same
176 behavioral assays as those used in the chemogenetic manipulations of *SepW1-Cre* mice (**Fig. 1**).

177 Adult *SepW1-En1/2* CKOs—showed a very small increase in sway length (**Fig. 3a**) with no
178 difference in total distance travelled compared to littermate controls (**Fig. 3b** and **Supplementary**
179 **Fig. 4a,b**). Additionally no deficits were observed in motor learning and performance between the
180 genotypes (**Fig. 3c,d** and **Supplementary Fig. 4c**). Unlike MedP-hM4Di mice (**Fig. 1o**), *SepW1-*
181 *En1/2* CKOs showed both normal acquisition and reversal learning compared to littermate
182 controls (**Fig. 3e**). There were no genotype differences in spatial working memory (**Fig. 3f**),
183 number of entries or distance travelled in the Y-maze (**Supplementary Fig. 4d,e**). Motor
184 coordination was also normal in early postnatal pups, using a surface righting reflex assay at P7
185 (**Fig. 3g**) and negative geotaxis assay at P7 and P11 (**Fig. 3h**). Together, these results
186 demonstrate that embryonic loss of the MedP eCN does not have a major impact on motor and
187 non-motor functions.

188

189 **Generation of mice in which all embryonic eCN are ablated using Diphtheria toxin**

190 One plausible explanation for the absence of a reversal learning deficit in mice with embryonic
191 loss of the medial eCN compared to adult inhibition of the same neurons could be the sufficiency
192 of the remaining interposed and lateral CN in the *SepW1-En1/2* CKOs. We therefore used an
193 intersectional pharmacogenetic approach to selectively kill all embryonic eCN soon after they are
194 born³⁰ as a means to determine the baseline requirement for eCN in a range of adult and neonatal
195 behaviors. Mice were engineered to express Diphtheria toxin subunit A (DTA) in the developing
196 eCN by combining an allele that expresses DTA only in cells that express both Cre and tTA
197 (*Igs7^{DRAGON-DTA/+}; Atoh1-tTA/+; En1^{Cre/+}* mice) and administering doxycycline from E13.5 onwards
198 (*eCN-DTA* mice) (**Fig. 4a**). Since the intersection of Cre and tTA expression is in immature eCN
199 and granule cell precursors (GCPs), by administering doxycycline after E13.5 cell killing is limited
200 to the eCN¹⁸. Immunostaining of sagittal sections at E17.5 revealed that 97.6% of the MEIS2+
201 eCN were missing in *eCN-DTA* mice compared to littermate controls (*Igs7^{DRAGON-DTA}* mice with
202 *Atoh1-tTA* or *En1^{Cre}* or neither transgene and fed doxycycline)(36±6.8 cells per mutant vs

203 1529±95.3 per control) (**Fig. 4b,c**). Quantification of NeuN+ cells in the CN of 7-week-old mice
204 demonstrated a major loss of large CN neurons (100-600 μm^2) in the *eCN-DTA* mice (**Fig. 4d**).
205 RNA *in situ* hybridization analysis confirmed the loss was mainly due to glutamatergic (*Slc17a6*)
206 eCN (**Fig. 4e**). RNAScope triple RNA hybridization analysis (n=3 per genotype) revealed that the
207 rare *Slc17a6*-expressing cells in *eCN-DTA* mice also expressed *Slc32a1* (GABAergic) and *Slc6a5*
208 (glycinergic) markers and were located preferentially in the MedA CN. Furthermore, similar
209 numbers of such triple positive cells were present in controls (**Fig. 4f** and **Supplementary Fig.**
210 **5a,b**). In the medial CN both the eCN and interneurons were absent in *eCN-DTA* mice, similar to
211 in *SepW1-En1/2* CKOs. We found that the remaining triple positive NeuN+ cells in the MedA CN
212 were not targeted by the *Atoh1-tTA* transgene (**Supplementary Fig. 5c**), despite being targeted
213 with *Atoh1-Cre* (**Supplementary Fig. 5d** and see refs^{18,22}). Therefore, all remaining NeuN+ cells
214 in the *eCN-DTA* mice are GABAergic (*Slc32a1*+) inhibitory CN neurons or triple glutamate-GABA-
215 glycine+ neurons.

216 We next examined the size and number of neurons in the cerebellar lobules. As expected,
217 cerebellar size and neuron numbers were reduced across the entire mediolateral axis in *eCN-*
218 *DTA* mice compared to littermate controls while the proportions and densities of each cell type
219 were maintained (**Fig. 4h-p**) As triple neurotransmitter positive eCN remain in the MedA, we
220 examined the growth of the vermis lobules that preferentially target the MedA. The anterior vermis
221 lobules (1-5) showed a significant reduction in area, but the magnitude was smaller than the
222 reduction in the central vermis (lobules 6-8) (**Supplementary Fig. 6**). The posterior vermis
223 (lobules 9 and 10) was not significantly reduced (**Supplementary Fig. 6**), consistent with the PCs
224 projecting outside the cerebellum to the vestibular nuclei^{31,32}. Thus, pharmacogenetic killing of the
225 developing eCN in *eCN-DTA* mice leads to loss of all *Slc17a6* single neurotransmitter positive
226 eCN and reduced cerebellar size with proportional scaling down of cell numbers throughout the
227 cerebellum.

228

229 **Loss of all eCN impairs motor coordination, but not motor learning and non-motor**
230 **behaviors.**

231 We repeated the same battery of behaviors in *eCN-DTA* mice of both sexes as in *SepW1-En1/2*
232 CKOs (**Fig. 3**). *eCN-DTA* mice of both sexes had motor coordination deficits in negative geotaxis
233 at P7 and P11 and righting reflex at P7 (**Fig. 5a,b**). Motor coordination continued to be abnormal
234 in adult *eCN-DTA* mice as they had a significant decrease in stride and increase in sway length
235 (**Fig. 5c**) and significantly reduced total distance travelled compared to littermate controls (**Fig.**
236 **5d** and **Supplementary Fig. 7a**), but with no difference in average velocity (**Supplementary Fig.**
237 **7b**). Interestingly, *eCN-DTA* mice showed normal motor learning (**Fig. 5e,f** and **Supplementary**
238 **Fig. 7c**). *eCN-DTA* mice showed normal reversal learning, although there was a main effect of
239 genotype in the WYM (**Fig. 5g**) with no change in swim speed (**Supplementary Fig. 7d**).
240 Moreover, there was no genotype difference in spatial working memory (**Fig. 5h,i**), although the
241 total distance travelled and number of arm entries were decreased in the Y-maze
242 (**Supplementary Fig. 7e-h**).

243 Since all eCN die in the embryo we tested additional cerebellar-associated non-motor
244 behaviors^{9,11,12}. In a more challenging spatial working memory test (plus-maze), *eCN-DTA* mice
245 showed no deficits (**Fig. 5i**), although the total distance travelled and number of arm entries were
246 decreased (**Supplementary Fig. 7g,h**). Compared to littermate controls *eCN-DTA* mice showed
247 no difference in social preference after normalizing for hypolocomotion (three-chambered social
248 approach assay^{33,34}; **Fig. 5j** and **Supplementary Fig. 7i,j**). We also did not find a genotype
249 difference in anxiety-like behavior (elevated plus maze) when normalizing for hypolocomotion
250 (**Fig. 5k** and **Supplementary Fig. 7k,l**). Finally, we did not find a genotype difference in total time
251 spent self-grooming (**Fig. 5l**). Altogether, the behavior analyses reveal that *eCN-DTA* mice,
252 lacking nearly all eCN, exhibit early motor coordination deficits that persist into adulthood, but
253 motor learning, cognitive, social, and anxiety-like behaviors are largely intact.

254

255 **Loss of *En1/2* in all eCN impairs motor coordination and learning, cognitive flexibility, and**
256 **spatial working memory**

257 Given a previous report that adult mice lacking excitatory activity in all eCN (*Atoh1-Slc17a6* CKO)⁵
258 have motor learning deficits that we did not observe following loss of all eCN (*eCN-DTA* mice),
259 we were prompted to analyze in more detail the behavior of a previously generated *En1/2*
260 conditional knockout mice (*Atoh1-En1/2* CKOs) that has motor learning deficits¹⁸. In *Atoh1-En1/2*
261 CKOs all eCN and GCs lack *En1/2* and the mice have an overall ~50% loss of eCN during
262 embryogenesis that includes a complete loss in the MedP and IntP eCN (**Supplementary Fig.**
263 **8a-e** and ref¹⁸). Further characterization revealed that similar to *SepW1-En1/2* CKOs
264 (**Supplementary Fig. 3e**) there was a significant loss of local interneurons, especially in the MedP
265 and IntP where all neurons are missing (**Supplementary Fig. 8b**).

266 *Atoh1-En1/2* CKO mice of both sexes had motor coordination deficits in negative geotaxis
267 at P7 and P11 compared to littermate controls (**Fig. 6a**), but no genotype difference in righting
268 reflex at P7 (**Fig. 6b**). Replicating our previous findings¹⁸, adult *Atoh1-En1/2* CKOs of both sexes
269 had motor coordination (**Fig. 6c**) and motor learning deficits (**Fig. 6e** and **Supplementary Fig.**
270 **9c**) and reduced total distance travelled (**Fig. 6d** and **Supplementary Fig. 9a**) and slower velocity
271 (**Supplementary Fig. 9b**) compared to littermate controls. Forelimb grip strength was normal (**Fig.**
272 **6f**). Thus, *Atoh1-En1/2* CKOs have motor coordination deficits detected by P7 that persist into
273 adulthood and adult motor learning deficits.

274 In terms of non-motor behaviors, *Atoh1-En1/2* CKOs showed both acquisition (day 1) and
275 reversal learning deficits in the WYM compared to littermate controls (**Fig. 6g**), which was not due
276 to a difference in swim speed (**Supplementary Fig. 9d**). There was no genotype difference in
277 spatial working memory (**Fig. 6h**) despite reduced total distance travelled and arm entries
278 (**Supplementary Fig. 9e,f**). However *Atoh1-En1/2* CKOs showed impaired spatial working
279 memory in the plus-maze (**Fig. 6i**) with no difference in total distance travelled or arm entries
280 (**Supplementary Fig. 9g,h**). *Atoh1-En1/2* CKOs showed no difference in social preference when

281 normalizing for hypolocomotion compared to littermate control mice (**Fig. 6j** and **Supplementary**
282 **Fig. 9i,j**). Also, genotype differences were not found in anxiety-like behavior (**Fig. 6k** and
283 **Supplementary Fig. 9k,l**) and self-grooming (**Fig. 6l**). Thus, *Atoh1-En1/2* CKOs have impaired
284 adult motor learning, acquisition/reversal learning and spatial working memory, in addition to the
285 motor coordination deficits as seen in *eCN-DTA* mice.

286

287 ***Atoh1-En1/2* CKOs have reduced but not ectopic cerebellothalamic projections**

288 One possible explanation for the differing behavioral outcomes in *Atoh1-En1/2* CKOs compared
289 to *eCN-DTA* mice is that the remaining eCN in *Atoh1-En1/2* CKOs exhibit aberrant projections to
290 the thalamus, a primary target region involved in behaviors studied. To address this question, we
291 mapped the projections to the thalamus of the remaining eCN in adult *Atoh1-En1/2* CKO and
292 littermate controls. We first examined whether the remaining MedA and IntA CN make ectopic
293 projections by injecting an *AAV2-hSyn-mCherry* virus or biotinylated dextran amine (BDA) into
294 the MedA or IntA, respectively (n=3 per genotype; **Fig. 7a,d**). Given the reduced neuron number
295 in the MedA and IntA CN, *Atoh1-En1/2* CKOs showed reduced mCherry+ or BDA+ axon terminals
296 in all thalamic nuclei compared to littermate controls (**Fig. 7b,e**), but importantly no obvious
297 ectopic projections were observed compared to littermate controls (**Fig. 7c,f**). We next performed
298 retrograde tracing from the intralaminar thalamic nuclei (ILM), which regulate motor learning and
299 cognitive flexibility^{35,36,37,38}. ILM receive strong projections from the MedP, interposed and lateral
300 CN, but not MedA²², allowing us to examine whether inputs to ILM from the remaining MedA (and
301 other nuclei) in *Atoh1-En1/2* CKOs are altered. We injected 10% Fluoro-Ruby preferentially into
302 the centrolateral (CL) or parafascicular (PF) thalamus, two nuclei within the ILM, of adult *Atoh1-*
303 *En1/2* CKOs and littermate controls (**Fig. 7g-i**). As expected, *Atoh1-En1/2* CKOs showed no
304 Fluoro-Ruby+ cells in the region of the MedP and IntP CN. Furthermore, no significant differences
305 in the total number of Fluoro-Ruby+ cells in the MedA, IntA, and lateral CN were detected
306 compared to littermate controls for CL injections (**Fig. 7j**) and PF injections (**Fig. 7k**). Thus, *Atoh1-*

307 *En1/2* CKOs have reduced cerebellothalamic projections, but the remaining CN do not make
308 ectopic projections.

309

310 **Diffusion MRI shows *Atoh1-En1/2* CKOs have connectivity changes outside the cerebellum**
311 **that are distinct from *eCN-DTA* mice**

312 Since the remaining eCN circuits in *Atoh1-En1/2* CKOs appear intact, we used high resolution ex
313 vivo dMRI^{39,40} to examine whether there are alterations in regional volume, connectivity, and
314 network properties outside of the cerebellum in adult *Atoh1-En1/2* CKO of both sexes as well as
315 *eCN-DTA* mice for comparison. We first examined regional volume in 10 distinct brain regions
316 (**Supplementary Fig. 10a**) and as expected a large reduction in the volume of the cerebellum
317 was detected in *Atoh1-En1/2* CKO compared to littermate controls (**Fig. 8a**). No changes in
318 regional volumes were seen except for a small but significant reduction in the midbrain (**Fig. 8b**),
319 when normalizing for an overall smaller brain in mutants (**Supplementary Fig. 10b,c**). Network
320 analysis using eight brain regions as nodes revealed a significant reduction in global efficiency
321 and small-worldness in *Atoh1-En1/2* CKOs compared to controls (**Fig. 8c-e** and **Supplementary**
322 **Fig. 10d-f**). Examining the number of streamlines between the thalamus and CN revealed the
323 expected significant reduction in *Atoh1-En1/2* CKOs compared to controls (**Supplementary Fig.**
324 **10g**). We further examined the number of streamlines between the ILM and three of its primary
325 downstream targets; the primary somatosensory cortex (SS), primary motor cortex (MO), and
326 dorsal striatum (DS). Interestingly, we observed a significant increase in the number of
327 streamlines in ILM-SS, ILM-MO, and ILM-DS circuits in *Atoh1-En1/2* CKOs compared to littermate
328 controls (**Fig. 8f-h,k-m** and **Supplementary Fig. 10h-j**). Furthermore, the number of streamlines
329 of the SS-DS and MO-DS circuits were significantly increased in *Atoh1-En1/2* CKOs compared
330 to littermate controls (**Fig. 8i,j,n,o** and **Supplementary Fig. 10k,l**).

331 In *eCN-DTA* mice, in addition to the expected reduction in cerebellum volume (**Fig. 8p**),
332 there was a small but significant increase in the cerebral cortex but no other changes in the rest

333 of the brain (**Fig. 8q**) when normalized to a smaller overall brain compared to littermate controls
334 (**Supplementary Fig. 10m-o**). There was a significant decrease in global efficiency, but no
335 changes in small-worldness in mutants (**Fig. 8r-t** and **Supplementary Fig. 10p,q**). Examining the
336 number of streamlines between the thalamus and CN confirmed a significant reduction in *eCN*-
337 *DTA* mice (**Supplementary Fig. 10r**). There were no genotype differences in the thalamo-cortico-
338 striatal connectivity that were detected in *Atoh1-En1/2* CKOs (**Fig. 8u-y** and **Supplementary Fig.**
339 **10s-w**). Thus, unlike *eCN-DTA* mice, *Atoh1-En1/2* CKOs show extracerebellar changes involving
340 an aberrant increase in connectivity of ILM-cortico-striatal circuits.

341

342 Discussion

343 Our study applied a novel combination of cell-type-specific genetic manipulations,
344 chemogenetics, dMRI and mouse behavior tests to uncover the requirements during development
345 of the *eCN* as a whole or the MedP in regulating motor and non-motor functions. We revealed
346 that the main requirement for the *eCN* if they are all removed in the embryo is for postnatal and
347 adult motor coordination. Furthermore, leveraging an *En1/2* CKO model we demonstrate that
348 seemingly intact *eCN* that lack critical developmental transcription factors can have major adverse
349 effects on cerebellar and extracerebellar circuits regulating adult motor learning and non-motor
350 behaviors.

351 We identified a genetic tool (*SepW1-Cre*) to manipulate the medial *eCN* from E14.5
352 onwards, adding to existing tools to manipulate all *eCN* or several subregions^{38,41,42,43,44,45,46,47}. By
353 comparing developmental loss (*SepW1-En1/2* CKOs) to adult inhibition of MedP *eCN* (MedP-
354 hM4Di) we show the neurons are critical for adult reversal learning (WYM) but dispensable if they
355 die embryonically. The MedP-hM4Di results are in line with impaired reversal learning after
356 indirectly inhibiting²⁷ or directly activating^{16,28} PCs that preferentially target the MedP *eCN* (lobule
357 6-8). Also, inhibition of the adult MedP *eCN* to ventrolateral periaqueductal gray⁴⁸ or MD⁴⁹ circuits
358 impairs fear extinction, another form of cognitive flexibility. Interestingly, manipulation of other

359 regions like Crus I neurons that target the lateral CN also show reversal learning deficits^{27,28}.
360 Furthermore, inhibiting lobule 6 versus Crus I PCs differentially alters c-Fos staining of recruited
361 forebrain regions during reversal learning²⁸, likely reflecting distinct downstream pathways^{16,22,50}.
362 Therefore, in *SepW1-En1/2* CKOs it is possible that the intact lateral eCN modify their activity to
363 carry out normal reversal learning.

364 On the contrary, we discovered that when all eCN are ablated embryonically, adult *eCN-*
365 *DTA* mice show normal reversal learning, indicating that reversal learning must be regulated by
366 extracerebellar brain regions in these mutants. Indeed, regional specific manipulation of the
367 intralaminar thalamus³⁶, dorsal striatum⁵¹, and cerebral cortex⁵² are sufficient to impair reversal
368 learning. Therefore, one possibility is that during development the corticostriatal or thalamostriatal
369 circuits are altered to confer reversal learning without cerebellar input. Similarly, extracerebellar
370 circuits can modulate social preference⁵³, spatial working memory⁵⁴, anxiety-like^{12,55}, and
371 stereotyped/repetitive⁵⁶ behaviors independent of the CN, which may explain why *eCN-DTA* mice
372 can perform these behaviors.

373 As expected for a cerebellar-specific developmental perturbation, *eCN-DTA* mice show
374 impaired neonatal and adult motor coordination^{5,57,58,59,60}. However, unlike when all eCN activity
375 is inhibited⁵ motor learning is not impaired in *eCN-DTA* mice. In addition to the eCN⁵⁸, the
376 GABAergic CN interneurons play a role in motor learning through their projections to the inferior
377 olive⁶¹. Therefore, the remaining GABAergic CN interneurons in *eCN-DTA* mutants might
378 contribute to motor learning, as well as extracerebellar circuits⁶² providing compensation.
379 Curiously, these possible sources for compensation in *eCN-DTA* mutants also are expected to
380 apply to mice lacking neurotransmission in all adult eCN⁵. Since *Atoh1^{Cre}* was used to generate
381 *Atoh1-Slc17a6* CKO⁵ mice rather than our intersectional approach that targets eCN, one
382 possibility is that one or more of the cell types outside the cerebellum that express *Atoh1^{Cre63}* are
383 responsible for the motor leaning deficits in adult *Atoh1-Slc17a6* CKO.

384 We found that although only ~50% of eCN are lost in *Atoh1-En1/2* CKOs, adult mutants
385 exhibit impaired motor learning, acquisition/reversal learning, and spatial working memory, which
386 is not seen in *eCN-DTA* mice. Of likely relevance, the remaining eCN in *Atoh1-En1/2* CKOs lack
387 the EN1/2 transcription factors, key regulators of cerebellar development^{18,64,65,66,67,68,69,70,71,72,73}.
388 The behavioral deficits in *Atoh1-En1/2* CKOs compared to *eCN-DTA* mice provides direct
389 evidence that dysfunctional eCN circuits due to genetic mutations can have worse outcomes than
390 losing the neurons embryonically. We propose that in *Atoh1-En1/2* CKOs, the remaining eCN
391 while targeting the correct thalamic nuclei are dysfunctional due to altered gene expression. In
392 line with these conclusions, removal of the cerebellum or vermis neonatally in genetically dystonic
393 rats^{74,75} or *weaver* mutants^{76,77} significantly rescues the adult motor coordination deficits seen in
394 both mutants. Circuits that comprise the ILM-cortico-striatal circuitry have been implicated in
395 motor learning^{36,37,78}, cognitive flexibility^{37,79,80}, and spatial working memory⁸¹. The excessive
396 connectivity seen in *Atoh1-En1/2* CKOs using dMRI might thus be caused by the remaining
397 *En1/2*-lacking eCN and contribute to their behavioral deficits.

398 In conclusion, our study highlights the importance of developing relevant models for
399 directly comparing developmental versus adult loss of neurons and the contribution of
400 dysfunctional neurons to understanding behavioral defects and possible compensation
401 (**Supplementary Fig. 11**). Moreover, our findings offer the potential to be leveraged for the
402 development of therapeutic avenues for patients with pediatric cerebellar injuries.

403 **Methods**

404 **Animals.** All animal care and procedures were performed according to the Memorial Sloan
405 Kettering Cancer Center and Weill Cornell Medicine Institutional Animal Care and Use Committee
406 guidelines. Mice were kept in a 12-h/12-h light/dark cycle and in temperature- and humidity-
407 controlled rooms and had *ad libitum* access to standard laboratory mouse chow and water. All
408 transgenic mouse lines were maintained on a mixed genetic background containing 129,
409 C57BL/6J, and Swiss Webster. For behavior analysis, males and females were analyzed
410 separately, but as there were no sex differences all final analyses combined the two sexes.
411 Estrous cycle was not evaluated for females. The following mouse lines were used in the study:
412 *Atoh1-Cre* (JAX #011104)⁸², *tetO-Cre* (JAX #006234)⁸³, *R26^{LSL-nls-tdTomato}* (Ai75D, JAX #025106)²⁴,
413 129S1/SvImJ (JAX #002448), Swiss Webster mice (Taconic Biosciences catalog #SW), *En1^{flox}*
414 (JAX #007918)⁷¹, *En2^{flox}* (JAX #008872)⁶⁴, *Atoh1-tTA*¹⁸, *En1^{Cre}* (JAX #007916)⁸⁴, *Igs7^{TRE-lox-tdTomato-STOP-lox-DTA*G128D}*
415 (or *Igs7^{DRAGON-DTA}*, JAX #034778)³⁰, and *SepW1-Cre* (MMRRC #036190-UCD)²³.
416 Details of all mouse strains used in the study are listed in **Table 1** and primers used for genotyping
417 are listed in **Table 2**.

418 Embryonic ablation of excitatory cerebellar nuclei (eCN) was achieved by crossing *Atoh1-*
419 *tTA/+; En1^{Cre/+}* mice with *Igs7^{DRAGON-DTA/DRAGON-DTA}* mice to generate *Atoh1-tTA/+; En1^{Cre/+};*
420 *Igs7^{DRAGON-DTA/+}* mice (eCN-DTA). Noon of the day that a vaginal plug was discovered was
421 designated as embryonic day 0.5 (E0.5). Doxycycline hyclate (Sigma D9891) was diluted in
422 drinking water (0.02 mg/mL) and provided at E13.5 (when neurogenesis of eCN is complete) until
423 postnatal day 28 (P28) for behavioral studies or otherwise until the end of the experiment and
424 replaced with fresh doxycycline every 3-4 days. To determine if the *Atoh1-tTA* transgene targets
425 the *Slc6a5*-expressing anterior medial eCN, *Atoh1-tTA/+; tetO-Cre/+; R26^{LSL-nls-tdTomato/+}* mice were
426 generated and administered doxycycline from E13.5 onwards. *Atoh1-En1/2* CKOs and *Atoh1-*
427 *En1/2* CKO; Ai75D mice were generated by crossing *Atoh1-Cre/+; En1^{flox/flox}; En2^{flox/flox}* males with
428 *En1^{flox/flox}; En2^{flox/flox}* or *En1^{flox/flox}; En2^{flox/flox}; R26^{LSL-nls-tdTomato/LSL-nls-tdTomato}* females, respectively.

429 Non-littermate control *Atoh1-Cre; Ai75D* mice were generated by crossing *Atoh1-Cre/+* males
430 with *R26^{LSL-nls-tdTomato/LSL-nls-tdTomato}* females. *SepW1-En1/2* CKO and *SepW1-En1/2* CKO; *Ai75D*
431 mice were similarly generated. *SepW1-Cre; Ai75D* mice were generated by crossing *SepW1-*
432 *Cre/+* or *SepW1-Cre/Cre* males with *R26^{LSL-nls-tdTomato/LSL-nls-tdTomato}* females. For all experiments and
433 analyses, investigators were blinded to the genotypes and experimental conditions.

434

435 **Behavioral assays.** All adult behavioral tests were conducted in a behavioral suite at Weill
436 Cornell Medicine (WCM) and early postnatal behavioral tests were conducted in an animal room
437 at Memorial Sloan Kettering Cancer Center (MSKCC). Six-week-old mice were transferred from
438 MSKCC to WCM two weeks prior to the start of the first behavioral test. Adult mice were
439 acclimated to the animal suite for 1 hour the day before testing. Before conducting each behavioral
440 test, mice were brought to the behavioral suite and left undisturbed for at least 1 hour before
441 testing. The order of each behavior test and age of animals (in brackets) for *eCN-DTA* and *Atoh1-*
442 *En1/2* CKO mice (and their littermate controls) was as follows: basal locomotor activity³³ (6 weeks),
443 three-chambered social approach^{33,34} (7 weeks), elevated plus maze³³ (8 weeks), self-grooming²⁷
444 (9 weeks), accelerating rotarod¹⁸, grip strength¹⁸ and footprint assay¹⁸ (11 weeks), spontaneous
445 alternation in dry Y-maze^{33,85} (12 weeks), water Y-maze^{16,59,86} (13 weeks). Plus-maze⁸⁷ was tested
446 with different groups of mice at 15 weeks (see details below). MedP-hM4Di mice (and control)
447 and *SepW1-En1/2* CKOs (and their littermate controls) followed the same order and age of
448 animals as *eCN-DTA* and *Atoh1-En1/2* CKOs, but were only tested for basal locomotor activity,
449 accelerating rotarod, grip strength, footprint assay, spontaneous alternation, and water Y-maze.
450 For *SepW1-En1/2* CKO, *Atoh1-En1/2* CKO, and *eCN-DTA* mice, negative geotaxis⁸⁸ (at P7 and
451 P11) and surface righting reflex⁸⁸ (P7) were tested. For MedP-hM4Di and control mice, clozapine
452 N-oxide dissolved in 0.9% saline (5 mg/kg, CNO, Enzo Life Sciences) was injected
453 intraperitoneally 30 minutes before the start of each behavioral testing. For accelerating rotarod
454 and water Y-maze, CNO was injected every day of behavioral testing. All behavioral experiments

455 were recorded with a Logitech C920 HD Pro Webcam (30 fps) and analyzed with ANY-maze
456 (Stoelting Co) or hand scored using BORIS software⁸⁹.

457

458 *Negative geotaxis.* Mice were tested for negative geotaxis reflex at P7 and P11 as previously
459 described⁸⁸. Mice were placed head down on a negative incline (-35°) platform that was covered
460 with a sterile poly-lined drape. Time until mice turned 180° in either direction was measured using
461 a stopwatch. The test was suspended if mice did not turn within 60 seconds (s) or fell down the
462 slope (considered failed trials). Failed trials were assigned a 60 s latency. All mice were tested
463 three trials per test day.

464

465 *Surface righting reflex.* Mice were tested for surface righting reflex at P7 as previously described⁸⁸.
466 Mice were placed in the supine position on a flat surface with a sterile poly-lined drape. The time
467 taken for each mouse to turn onto their four paws was measured. All mice were tested for three
468 trials per test day.

469

470 *Basal locomotor activity.* Mice were placed in a polycarbonate test chamber (27.3 cm x 27.3 cm)
471 equipped with three infrared beam arrays. Horizontal locomotor activity was monitored by
472 computer-assisted activity monitoring software (Med Associates). For each test session, animals
473 were placed in the chamber and recorded for 1 hour without interruption with no incandescent
474 lighting³³. Locomotor activity was measured as total distance traveled in centimeters.

475

476 *Three-chamber social approach.* Mice were tested with a modified version of the three-chamber
477 social approach and social novelty assays as described previously^{33,34}. All testing was conducted
478 in the three-chamber apparatus (Ugo Basile sociability apparatus, Stoelting Co) in a room with 30
479 lux lighting at the center of each chamber (1~2 lux difference across chambers) and a ceiling-

480 mounted camera for ANY-maze tracking. Two days before testing, age- and sex-matched
481 129S1/SvImJ mice were habituated to the wire cup (see ref³⁴ for details). After 1-hour habituation
482 to the testing room, two 129S1/SvImJ mice were placed individually under a wire cup (3.8 cm
483 bottom diameter, rust-proof/rust-resistant, noncorrosive, steel wire pencil cups) in the left or right
484 chamber of the apparatus. The entrance to each chamber was blocked. 129S1/SvImJ mice were
485 observed for 10 min for behaviors that are potentially disruptive, such as bar-biting, excessive
486 self-grooming, circling, or clinging to the side bars with all four paws. Only 129S1/SvImJ mice
487 showing docile behavior were used as novel mice in the social approach and novelty testing.

488 On the day of testing, mutant or control mice were placed in the center of an empty
489 apparatus to freely explore all three chambers for 10 min. During the 10 min habituation, empty
490 wire cups were placed in both left and right chamber. Mice were briefly taken out of the apparatus
491 and a novel object (orange rectangle block) and a novel mouse were placed under each wire cup.
492 The location of the novel mouse was randomly assigned across each subject mouse. Test mice
493 were placed back into the center chamber and allowed to freely explore for 5 min. Test mice were
494 kept in a separate cage until all animals from its original home cage were tested. Time spent in
495 each chamber and time spent in the contact zone (nose within a 2 cm radius around the wire cups)
496 were calculated by automated detection.

497
498 *Elevated plus maze.* Mice were placed in the center of an elevated plus maze (L x W x H = 50 cm
499 x 5 cm x 50 cm and 38 cm above the floor) for 10 min with 15 lux lighting in the open arms and 5
500 lux lighting in the closed arms³³. A ceiling-mounted camera for ANY-maze tracking was used to
501 measure time spent in and entries into each arm.

502
503 *Self-grooming.* Mice were placed in a clean cage for 10 min to habituate to the test arena with 25-
504 30 lux lighting²⁷. After habituation, mouse activity was recorded for 10 min. Time spent grooming
505 was hand scored by an experimenter blind to the genotype.

506

507 *Accelerating rotarod and grip strength.* Mice were tested using an accelerating rotarod protocol
508 as previously described¹⁸ with 30 lux lighting. Mice were put on a rotarod (47650, Ugo Basile)
509 rotating at 10 rpm until all mice (3~5 mice tested simultaneously) were facing forward for at least
510 5 s. The rod was then accelerated from 10 rpm to 40 rpm over 5 min. Mice were tested for 3 trials
511 per day across 3 consecutive days. Animals rested for 10 min in their home cage between each
512 trial. Latency to fall (seconds) was recorded for each animal. If a subject mouse held onto the rod
513 and rotated 3 consecutive times, the latency at which the mouse first started to rotate with the rod
514 was recorded as the latency to fall and the mouse was returned to their home cage. If a subject
515 mouse repeatedly fell within 10-15 s after the start of each trial, the mouse was excluded from the
516 final analysis. If mice did not fall throughout the entire trial, 300 s was assigned as latency to fall.
517 The following day after the accelerating rotarod test, forelimb grip strength was measured using
518 a horizontal grip bar (1027SM Grip Strength meter with single sensor, Columbus Instruments).
519 Mice were allowed to hold the triangle grip bar while being gently pulled away by the base of their
520 tail with their body parallel to the bench. The average of 5 measurements was normalized to the
521 mouse's body weight (force/gram). Animals rested 5 min in their home cage between each
522 measurement.

523

524 *Footprint assay.* Mice were tested using a footprint assay as previously described with 30 lux
525 lighting¹⁸. After forepaws and hindpaws were painted with different nontoxic acrylic paint colors
526 (red/blue or orange/purple, Crayola), mice were allowed to walk through a plexiglass tunnel (L x
527 W x H = 50 cm x 10 cm x 15 cm) lined with a strip of paper. A dark box was placed at the end of
528 the plexiglass tunnel. Each mouse was tested three times, and three gait parameters (stride, sway,
529 and stance) were measured from each run and averaged.

530

531 *Y-maze*. Mice were tested using a Y-shaped maze with equal length arms (L x W x H = 33.0 cm
532 x 7.6 cm x 38.1 cm) as described previously^{33,85} with 20 lux lighting at the bottom of the center of
533 the arena. Mice were placed in the center of the arena and allowed to freely explore the arena for
534 5 min. A ceiling-mounted camera for ANY-maze tracking was used to record the distance travelled
535 in the maze. The sequence of arm entries and number of entries to each arm was manually scored.
536 The percentage of spontaneous alternation was calculated as previous described^{33,85}.

537

538 *Water Y-maze*. Mice were tested using an adapted version of the water Y-maze test as described
539 previously^{16,59,86} with no incandescent lighting (red light for experimenter). The same Y-shape
540 maze used in the dry Y-maze test above was filled with room temperature water colored with non-
541 toxic white paint to be opaque. After dry Y-maze testing and ~1 week prior to testing, mice were
542 placed at the base of one of the Y-maze arms (filled with paint but no hidden platform) and allowed
543 to freely swim for 3 minutes. Average velocity was measured using ANY-maze tracking software.
544 On day 1, mice were placed in the base of one arm of the Y-maze and allowed to swim for 60 s
545 without a platform present to further habituate the mice to the arena. On the next three days (2-
546 4), a white platform was submerged about 1 cm below the surface of the water at the end of one
547 of the arms of the Y-maze. The location of the platform was randomly assigned to either the left
548 or right arm relative to the starting arm (base arm). Mice were placed in the base of the Y-maze
549 and latency to find the platform was recorded. The number of correct trials were recorded only
550 when the first arm entered was the arm with the platform and the mouse found the platform without
551 entering another arm. Once the mouse found the platform, the mouse was allowed to sit on it for
552 15 s and removed from the Y-maze and placed under a heat lamp in an empty cage. If the mouse
553 did not find the platform within 35 s, it was placed onto the platform for 20 s. All mice were run for
554 the same trial before repeating the process for all 15 trials. On average 10-15 mice were run
555 during one session. This procedure was repeated with each animal for 15 trials per day for 3
556 consecutive days. For days 5-7, the location of the platform was switched to the opposite arm

557 from which the mouse was initially trained on days 2-4. The same procedure as days 2-4 were
558 repeated. Each day, at the end of the set of 15 trials, the mouse was towed dry and placed
559 under a heat lamp for 5 min before returning to its home cage. The correct choices (when the first
560 arm entered was the correct arm and the mouse found the platform) and latency to find platform
561 were hand scored using a stopwatch during each trial.

562
563 *Plus-maze*. Mice were tested using a plus-shape maze with equal length arms (L x W x H = 30.48
564 x 5.08 x 15.24 cm) as described previously⁸⁷ with incandescent lighting. Mice were placed in one
565 arm of the maze designated the base of the arena and allowed to freely explore the arena for 12
566 min each day for a total of 4 days (day 1 was considered habituation to the arena). A ceiling-
567 mounted camera for ANY-maze tracking was used to record the distance travelled in the maze.
568 The sequence of arm entries and number of entries into each arm was scored using a custom
569 MATLAB script. The percentage spontaneous alternation was calculated as previous described⁸⁷
570 and the last 3 days of the behavioral testing was averaged for final analysis. As previously
571 described, the estimated chance level performance for the plus maze test is 22.2% spontaneous
572 alternations⁸⁷. For *Atoh1-En1/2* CKOs, mice were tested in two different locations: Weill Cornell
573 Medicine (New York, NY) and University of Tennessee Health Science Center (Memphis, TN).
574 Data from both institutions were pooled as the results were consistent. For *eCN-DTA* mice, all
575 mice were tested at Weill Cornell Medicine (New York, NY).

576
577 **Stereotaxic Injections.** Mice were anesthetized with 2.5% isoflurane and 80% O₂ and head-fixed
578 in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) equipped with digital manipulator
579 arms (Stoelting Co, Wood Dale, IL). A nose cone was used to deliver isoflurane to maintain
580 anesthesia. Mice were given a subcutaneous injection of meloxicam (2 mg/kg) and 0.1 mL of 0.25%
581 Marcaine around the incision site. After exposing the skull, craniotomies were made with an
582 electric drill (Stoelting CO, Wood Dale, IL) with a ball bur attached. A Neuros 7000 series 1 μ L

583 Hamilton syringe with a 33-gauge needle (Reno, NV) connected to a remote automated
584 microinfusion pump (KD Scientific, Holliston, MA) was used for delivery of tracers or viral
585 constructs at a rate of 100 or 50 nL/min, respectively. Details of dye, viruses, and stereotaxic
586 coordinates are provided in **Table 3**. Following infusion, the needle was left in place for 5 min and
587 then slowly manually retracted. Mice were placed on a heat pad for at least 30 min post-surgery
588 before being returned to their home cage. Mice were monitored for three days post-surgery to
589 ensure recovery. Brains were collected and imaged (see below) to confirm viral expression and
590 injection placements and no misplacements were found.

591
592 **Tissue preparation.** For all histological analyses, mice were anesthetized with isoflurane and
593 then perfused transcardially with room temperature (RT) phosphate buffered saline (PBS) with
594 heparin (0.02 mg/mL) and then ice-cold 4% paraformaldehyde (PFA, Electron Microscopy
595 Sciences, catalog no: 15714). Brains were dissected and post-fixed in 4% PFA overnight at 4°C
596 and cryopreserved in 30% sucrose in PBS for ~2 days at 4°C. Brains were embedded in Tissue-
597 Tek OCT compound (Sakura Finetek). Coronal serial cryosectioning was performed at either 40
598 um (6 series) or 100 um (3 series) and collected in 0.01M phosphate buffer (PB) with 0.02%
599 sodium azide and kept at 4°C until further processing. For long-term storage, sections were
600 transferred to 24-well plates with cryoprotectant (30% sucrose and 30% ethylene glycol in 0.1M
601 PB) and stored at -20°C. Sagittal serial cryosectioning was performed at either 14 um (10 series)
602 or 30 um (6 series) and collected on charged glass slides (Fisherbrand ColorFrost Plus) and
603 stored at -20°C until further processing. Details of reagents are listed in **Table 1**.

604 For single molecular fluorescence *in situ* hybridization, tissue was prepared as previously
605 described⁹⁰. Mice were anesthetized with isoflurane and then perfused transcardially with RT 0.9%
606 saline with 10 units/mL heparin (Sigma Aldrich, H3393-50KU) followed by RT 4% PFA in 0.2M
607 phosphate buffer (PB). Brains were dissected and post-fixed in the same fixative overnight at RT.

608 Brains were cryopreserved by incubating in 15% sucrose in 0.2M PB overnight followed by an
609 overnight incubation in 30% sucrose in 0.2M PB. Brains were embedded in Tissue-Tek OCT
610 compound and stored at -80°C until further processing. Coronal serial cryosectioning was
611 performed at 30 um and sections were stored in cryoprotectant solution at -20°C until further
612 processing. Details of reagents are listed in **Table 1**.

613

614 **Hematoxylin and eosin (H&E) staining.** All reagents for H&E staining were obtained from
615 Richard-Allan Scientific: hematoxylin 2 solution (catalog no: 7231), eosin-Y (catalog no: 7111),
616 bluing reagent (catalog no: 7301), clarifier 2 (catalog no: 7402). Slides were first washed in PBS
617 for 5 min and incubated in hematoxylin 2 solution for 3 min. Slides were rinsed in deionized water
618 (diH₂O) and immersed in staining reagents for 1 min each (diH₂O, bluing reagent, diH₂O, clarifier
619 2, diH₂O). After dehydration and defatting (dH₂O-70% ethanol-95%-95%-100%-100%-xylene-
620 xylene-xylene, 1 min each) slides were mounted with a coverslip and DPX mounting medium
621 (Electron Microscopy Sciences). Details of reagents are listed in **Table 1**.

622

623 **Immunofluorescence.** For slide-mounted sections, slides were washed three times in PBS for 5
624 min. If necessary, antigen retrieval was then performed by immersing slides in sodium citrate
625 buffer (10 mM sodium citrate with 0.05% Tween-20, pH 6.0) at 95°C for 20 min followed by
626 washing with PBS. Slides were then incubated in blocking buffer (5% BSA in 0.4% Triton-X100 in
627 PBS (PBST)) for 1 hour at 4°C. Primary antibody solution in blocking buffer was then applied
628 overnight at 4°C. Primary antibody information and dilutions are listed in **Tables 1 and 4**. Slides
629 were then washed with RT 0.1% PBST three times and incubated in secondary antibody solution
630 in blocking buffer (1:500) for 1 hour at RT. Slides then were incubated in Hoechst (Invitrogen,
631 catalog no: H3569 diluted 1:1000 in PBS) for 10 min and washed with PBS three times and cover-
632 slipped with Fluoro-Gel (Electron Microscopy Sciences, catalog no: 17985-10).

633 For free-floating sections, sections were first washed three times in PBS for 10 min.
634 Sections then were incubated in blocking buffer (10% normal donkey serum in 0.5% PBST,
635 Sigma-Aldrich, catalog no: D9663-10ML) for 1 hour at RT before incubating in primary antibody
636 solution (2% normal donkey serum in 0.4% PBST) for 24-48 hours at 4°C. Slides were washed in
637 PBS three times and incubated in secondary antibody solution (1:500 in 2% normal donkey serum
638 in 0.4% PBST) for 2 hours at RT. Slides then were incubated in Hoechst (1:1000 in PBS) for 10
639 min and washed with PBS three times. Sections were mounted on glass slides and after sections
640 had fully dried, cover-slipped with Fluoro-Gel (Electron Microscopy Sciences).

641
642 **Immunohistochemistry.** All steps were performed at RT, unless specified. Cryosectioned tissue
643 mounted on slides were washed three times in PBS for 5 min (hereafter PBS washes). Antigen
644 retrieval was achieved by immersing sections in sodium citrate buffer at 95°C for 40 min and
645 washing in PBS. Slides were then treated with 50% methanol (in deionized H₂O) with 0.03%
646 H₂O₂ for 1 hour and washed with PBS. Primary antibody solution in blocking buffer (5% BSA in
647 0.4% PBST) was applied overnight at 4°C. After washing in PBS, a biotinylated secondary
648 antibody in blocking buffer (1:500) was applied for 1 hour, followed by PBS washes. Vectastain
649 Elite ABC HRP solution (Vector Labs, Burlingame, CA, USA; PK-6100) in blocking buffer (1:500
650 for A and B) was applied for 1 hour, followed by PBS washes. Sections were washed in 0.175 M
651 sodium acetate (in ddH₂O) and incubated in either standard DAB (0.02% 3,3'-Diaminobenzidine
652 tetrahydrochloride (Sigma-Aldrich, D5905), 2.5% H₂O₂ in 0.175 M sodium acetate) or Nickel-
653 enhanced DAB (Ni-DAB) solution (addition of 2.5% NiSO₄ in standard DAB solution) for 20 min.
654 DAB or Ni-DAB reaction was stopped by washing sections in 0.175 sodium acetated followed by
655 PBS washes. Sections were mounted on glass slides and dried overnight. After dehydration and
656 defatting (dH₂O-70% ethanol-95%-95%-100%-100%-xylene-xylene-xylene, 1 min each) slides
657 were mounted with a coverslip using DPX mounting medium (Electron Microscopy Sciences).

658

659 **Single molecule fluorescence *in situ* hybridization.** Tissue was treated according to the
660 RNAscope Multiplex Fluorescent Assay v2 manufacturer's instructions and reagents from
661 Advanced Cell Diagnostics (Hayward, CA). Details of reagents are listed in **Table 1**. Sections
662 were rinsed twice (5 min each) in RNAase and DNAase free PBS before mounting onto Superfrost
663 Plus coated slides (VWR, catalog no: 48311-703) in RNase- and DNase-free PBS. Slides were
664 dried overnight and heated for 1 hour at 60°C. Slides were pretreated with target retrieval buffer
665 for 10 min at 95-100°C, then treated with Protease III for 30 min at 40°C, followed by a probe
666 incubation for two hours at 40°C. The probes used were: Mm-*Slc32a1*-C1, Mm-*Slc17a6*-C2 and
667 Mm-*Slc6a5*-C3. After probe incubation, slides underwent three amplification steps, followed by
668 developing horseradish peroxidase signal fluorescence with TSA-based fluorophores. Hoechst
669 33258 was used as a counterstain and slides were dried for 15 min before cover-slipping with
670 Fluoro-Gel.

671
672 **Double labeling by RNA *in situ* hybridization and protein immunofluorescence.** Sagittal
673 sections (14 um) were first processed for *in situ* hybridization of *Slc6a5* as described previously⁹¹.
674 Briefly, probes were *in vitro* transcribed from PCR-amplified templates prepared from cDNA
675 synthesized from an adult cerebellum lysate. The forward (5'-GTATCCCACGAGATGGATTGTT-
676 3') and reverse (5'- CCATACAGAACACCCTCACTCA-3') primers used for PCR amplification
677 were based on the Allen Brain Atlas. Primers were flanked in the 5' with SP6 (antisense) and 3'
678 with T7 (sense) promoters. After visualizing the probe, slides were incubated in 4% PFA overnight
679 at 4°C. Following PBS washes, slides were incubated in sodium citrate buffer (10 mM sodium
680 citrate with 0.05% Tween-20, pH 6.0) at 95°C for 40 min. Slides were placed in blocking buffer for
681 one hour and then incubated in primary antibody solution (anti-RFP at 1:500 in blocking buffer)
682 overnight at 4°C. Slides were washed with 0.1% PBST three times and incubated in secondary
683 antibody solution in blocking buffer (1:500) for 1 hour at RT. Slides were then incubated in Hoechst

684 (1:1000 in PBS, Invitrogen, catalog no: H3569) for 10 min and washed with PBS three times and
685 cover-slipped with Fluoromount-G (ThermoFisher Scientific, catalog no: 00-4958-02).

686

687 **Microscopy, image processing, and analyses.** All images were acquired with a DM6000 Leica
688 fluorescent microscope (Leica Camera, Wetzlar, Germany) or NanoZoomer Digital Pathology
689 (Hamamatsu Photonics, Shizuoka, Japan). Images were processed or analyzed using Fiji⁹² or
690 Photoshop (Adobe Inc., San Jose, CA, USA). Cell counts for littermate controls, *SepW1-En1/2*
691 *CKO*, *Atoh1-En1/2 CKO*; *Ai75D*, *Atoh1-Cre*; *Ai75D*, and *eCN-DTA* mice were manually obtained
692 using the Cell Counter plugin for Fiji or semi-automated using a custom script using the Analyze
693 Particle plugin for Fiji as previously described¹⁸.

694 The CN subregions were delineated for quantifying the recombination efficiency in
695 *SepW1-Cre*; *Ai75D* mice using MEIS2 staining and the mouse brain atlas⁹³. 10-14 brain slices
696 that were 40-um apart were analyzed. The percentage of tdTomato+ cells across the CN were
697 calculated for each animal (total n=4 mice) and averaged. The same slides were used to calculate
698 the percentage of tdTomato+ cells in the medial CN that were co-labeled for MEIS2 (total n=4
699 mice) and averaged.

700

701 **Brain sample preparation for ex vivo dMRI.** Mice were transcardially perfused with RT PBS
702 containing heparin and then 4°C 4% PFA. Brains were kept inside the skull, but skin, eyeballs
703 and muscle surrounding was removed and then kept overnight in 4% PFA at 4°C. Samples were
704 then stored in PBS with 0.02% sodium azide until imaging. One week before imaging, samples
705 were equilibrated with Gadodiamide (0.2 mM) in PBS at 4°C and scanned by an experimenter
706 blind to the sex and genotype.

707

708 **High resolution ex vivo dMRI.** Imaging of the brains was conducted as previously described^{39,40}.
709 High resolution ex vivo dMRI datasets were acquired on a horizontal 7T MR scanner (Bruker

710 Biospin, Billerica, MA, USA) using a 72-mm conventional circularly polarized birdcage
711 radiofrequency resonator (Bruker Biospin, Ettlingen, Germany) for homogeneous transmission in
712 conjunction with a four-channel receive-only phased array CryoProbe (CRP, Bruker Biospin,
713 Ettlingen, Germany) and a modified 3D diffusion-weighted gradient-and-spin-echo (DW-GRASE)
714 sequence⁹⁴ (TE/TR: 35 ms/ 400 ms, b-value: 5000 s/mm², no. of diffusion directions: 60,
715 resolution: 0.1 mm³ isotropic, acquisition time: 10.6h).

716

717 **dMRI data processing.** dMRI rawdata was processed using a pipeline demonstrated in our
718 earlier studies^{39,40}. In brief, the following steps were followed for each subject: 1) removal of
719 signals from non-brain tissue in the dMRI datasets using AMIRA (ThermoFisher
720 Scientific, <https://www.thermofisher.com>), 2) Correction for specimen displacements using rigid
721 alignment implemented in DTIStudio⁹⁵, 3) calculation of diffusion tensor, fractional anisotropy, and
722 fiber orientation and distribution maps Using MRtrix⁹⁶ (<https://www.mrtrix.org/>), 4) regional
723 volumetric analysis, and 5) streamline tractography between the selected pairs of brain regions
724 or nodes.

725

726 **Volumetric analysis.** For regional brain volumetric analysis, each subject was mapped to a high-
727 resolution mouse brain atlas³⁹. Whole brain volume or 10 regional volumes (cortex – CTX,
728 olfactory area – OLF, hippocampus – HPF, amygdala – AMY, striatum – STR, pallidum – PAL,
729 thalamus – TH, hypothalamus – HY, midbrain – MB, and cerebellum – CB) were calculated.

730

731 **Streamline tractography and structural connectome generation.** Structural connectivity
732 between nodes and the structural connectome were constructed as previously reported^{39,40,97}. In
733 short, eight nodes (anterior cingulate cortex – ACA, motor cortex – MO, somatosensory cortex –
734 SS, HPF, STR, AMY, TH, and HY) were included to construct the node-to-node SC maps using
735 streamline tractography as implemented in MRtrix by seeding (n = 50,000) within the seed region

736 with minimum streamline length of 3 mm, FOD cut-off 0.05, step size 0.025, and angle 45°.
737 Excluding the intra-regional connectivity, in total 28 connections per subject were generated,
738 which were subsequently used to construct the subject-specific structural connectome⁴⁰.

739

740 **Global network analysis.** Brain global network properties, global efficiency (Geff) and small-
741 worldness (SW), were evaluated as previously described⁹⁷ using principles of graph theory⁹⁸ via
742 GRETNA software⁹⁹. Geff represents the efficiency of distant information transfer in a network
743 and was defined as the inverse of the average characteristic path length between all nodes in the
744 network. Brain network with short average path length between nodes and high degree of
745 interconnectedness in local networks is considered to have SW properties. SW was computed by
746 normalizing the network with respect to 1000 simulated random networks with equal distribution
747 of edge weight and node strength as reported previously¹⁰⁰.

748

749 **Statistics.** No statistical methods were used to predetermine sample sizes, but our sample sizes
750 are similar to those reported previously^{18,33,59}. At least three different litters were used for all
751 experiments (cell counting and behavior). No litter-related effects were seen in behavioral studies.
752 Experimenters were blind to mouse genotypes during behavior analysis and quantifications. All
753 data were subject to the Shapiro-Wilk test and Q-Q plots were generated to evaluate normality. If
754 one or more dependent variable(s) failed the normality test, a non-parametric test was used. For
755 behavioral experiments, outliers were defined if at least one dependent variable was more than
756 mean+2×SD or less than mean-2×SD. Some additional criteria for outliers are indicated for each
757 behavioral test (see above). A given outlier was not consistent across experiments. All statistical
758 analyses were carried out with GraphPad Prism 8 software. Comparisons between two groups
759 were analyzed using parametric test (unpaired *t*-test) or non-parametric test (Mann-Whitney test).
760 The Holm-Šídák method was used for multiple unpaired *t*-test comparisons. Wilcoxon signed-
761 rank test (null hypothesis = 50%) was used to test normal social preference in the three-

762 chambered social approach test. Ordinary two-way ANOVA was used to compare means across
763 two or more dependent variables. Repeated measures two-way ANOVA with Šídák's multiple
764 comparisons test were used for basal locomotion, accelerating rotarod, and water Y-maze. A
765 three-way ANOVA was used to examine the effects of sex and genotype on behavior, but as there
766 were no sex differences (data not shown), final analyses included both males and females. Data
767 are presented as mean \pm SEM or mean \pm SD as indicated in each figure legend. Mean differences
768 were considered significant if $P < 0.05$.

769

770 **Acknowledgements**

771 We thank all members of the Joyner, Rajadhyaksha, Heck, and Zhang laboratories over the past
772 five years for insightful discussions and technical support. We thank Alexander Walsh, Narmin
773 Mekawy, Diego Scala Chavez, and Dr. Arlene Martinez-Rivera for their excellent support from the
774 Rajadhyaksha lab. We thank Drs. Kristen Pleil (Weill Cornell Medicine), Peter Tsai (UT
775 Southwestern), and Jacqueline Crawley (UC Davis) for their advice and input on data
776 interpretation and technical support for DREADDs and behavioral testing. We thank Dr. Choong
777 Heon Lee for his help with diffusion MRI scanning and post-processing. This work was supported
778 by grants from the NIH to Alexandra L. Joyner (R37MH085726 and R01NS092096), Andrew S.
779 Lee (NICHD T32HD060600), Anjali M. Rajadhyaksha (R01MH118934, R01MH125006,
780 R01DA029122, R01DA050454), Natalia V. De Marco Garcia (2R01MH110553, 1R01MH125006,
781 1R01NS116137), Detlef H. Heck (R01MH112143), and Jiangyang Zhang (R01NS102904).
782 Alexandra L. Joyner is also supported by an NCI Cancer Center Support Grant (CCSG, P30
783 CA08748) and the Cycle for Survival. Andrew S. Lee was supported by a Weill Cornell Medicine
784 Clinical & Translational Science Center Predoctoral Training Award (TL1TR002386) from the
785 National Center for Advancing Translational Sciences. Alina Gubanova was supported by a
786 Fordham College at Lincoln Center Dean's Undergraduate Research and Creative Practice Grant.

787 Anjana Krishnamurthy was supported by a Dorris J. Hutchison Predoctoral Fellowship. Anjali M

788 Rajadhyaksha was supported by the Weill Cornell Autism Research Program.

789

790 **Contributions**

791 A.S.L., A.M.R., T.M.A., D.H.H., J.Z., A.L.J. formulated experiments and analysis. A.S.L., A.G.,

792 D.N.S., Y.L., Z.L., A.K. performed experiments and analysis. T.M.A. and J.Z. carried out the

793 mouse diffusion MRI experiments and analysis. N.V.D.M.G. provided the *SepW1-Cre* mice. A.S.L.,

794 T.M.A., A.M.R., and A.L.J. prepared the manuscript.

795

796 **Competing interests**

797 All authors declare to have no actual or potential conflict of interest including any financial,

798 personal, or other relationships with other people or organizations within three years of beginning

799 the submitted work that could inappropriately influence, or be perceived to influence, their work.

800

801 **Data availability**

802 Any additional information and requests for reagents and resources should be directed to and

803 will be satisfied by the lead contact ALJ.

804

805 **Code Availability**

806 All data reported in this study and the analysis codes used are available upon request.

807 **References**

- 808 1. Albazron FM, *et al.* Pediatric postoperative cerebellar cognitive affective syndrome follows
809 outflow pathway lesions. *Neurology* **93**, e1561-e1571 (2019).
- 810 2. Korah MP, *et al.* Incidence, risks, and sequelae of posterior fossa syndrome in pediatric
811 medulloblastoma. *Int J Radiat Oncol Biol Phys* **77**, 106-112 (2010).
- 812 3. Robertson PL, *et al.* Incidence and severity of postoperative cerebellar mutism syndrome
813 in children with medulloblastoma: a prospective study by the Children's Oncology Group.
814 *J Neurosurg* **105**, 444-451 (2006).
- 815 4. Stoodley CJ, Limperopoulos C. Structure-function relationships in the developing
816 cerebellum: Evidence from early-life cerebellar injury and neurodevelopmental disorders.
817 *Semin Fetal Neonatal Med* **21**, 356-364 (2016).
- 818 5. van der Heijden ME, *et al.* Glutamatergic cerebellar neurons differentially contribute to the
819 acquisition of motor and social behaviors. *Nat Commun* **14**, 2771 (2023).
- 820 6. Herculano-Houzel S. Coordinated scaling of cortical and cerebellar numbers of neurons.
821 *Front Neuroanat* **4**, 12 (2010).
- 822 7. Herculano-Houzel S, Mota B, Lent R. Cellular scaling rules for rodent brains. *Proc Natl*
823 *Acad Sci U S A* **103**, 12138-12143 (2006).
- 824 8. Prati JMP-S, A.; Gianlorenco, A. C. L. The cerebellum and its connections to other brain
825 structures involved in motor and non-motor functions: a comprehensive review. *Behav*
826 *Brain Res*, (2024).
- 827 9. Kobschull JM, *et al.* Cerebellum Lecture: the Cerebellar Nuclei-Core of the Cerebellum.
828 *Cerebellum*, (2023).
- 829 10. Novello M, Bosman LWJ, De Zeeuw CI. A Systematic Review of Direct Outputs from the
830 Cerebellum to the Brainstem and Diencephalon in Mammals. *Cerebellum* **23**, 210-239
831 (2024).

- 832 11. Rudolph S, *et al.* Cognitive-Affective Functions of the Cerebellum. *J Neurosci* **43**, 7554-
833 7564 (2023).
- 834 12. Zhang XY, *et al.* A role for the cerebellum in motor-triggered alleviation of anxiety. *Neuron*,
835 (2024).
- 836 13. Darmohray DM, Jacobs JR, Marques HG, Carey MR. Spatial and Temporal Locomotor
837 Learning in Mouse Cerebellum. *Neuron* **102**, 217-231 e214 (2019).
- 838 14. Fujita H, Kodama T, du Lac S. Modular output circuits of the fastigial nucleus for diverse
839 motor and nonmotor functions of the cerebellar vermis. *Elife* **9**, (2020).
- 840 15. Judd EN, Lewis SM, Person AL. Diverse inhibitory projections from the cerebellar
841 interposed nucleus. *Elife* **10**, (2021).
- 842 16. Kelly E, *et al.* Regulation of autism-relevant behaviors by cerebellar-prefrontal cortical
843 circuits. *Nat Neurosci* **23**, 1102-1110 (2020).
- 844 17. Liu XX, *et al.* BOD1 regulates the cerebellar IV/V lobe-fastigial nucleus circuit associated
845 with motor coordination. *Signal Transduct Target Ther* **7**, 170 (2022).
- 846 18. Willett RT, *et al.* Cerebellar nuclei excitatory neurons regulate developmental scaling of
847 presynaptic Purkinje cell number and organ growth. *Elife* **8**, (2019).
- 848 19. Sugihara I, Fujita H, Na J, Quy PN, Li BY, Ikeda D. Projection of reconstructed single
849 Purkinje cell axons in relation to the cortical and nuclear aldolase C compartments of the
850 rat cerebellum. *J Comp Neurol* **512**, 282-304 (2009).
- 851 20. Corrales JD, Blaess S, Mahoney EM, Joyner AL. The level of sonic hedgehog signaling
852 regulates the complexity of cerebellar foliation. *Development* **133**, 1811-1821 (2006).
- 853 21. Fleming JT, *et al.* The Purkinje neuron acts as a central regulator of spatially and
854 functionally distinct cerebellar precursors. *Dev Cell* **27**, 278-292 (2013).
- 855 22. Keschull JM, *et al.* Cerebellar nuclei evolved by repeatedly duplicating a conserved cell-
856 type set. *Science* **370**, (2020).

- 857 23. Gerfen CR, Paletzki R, Heintz N. GENSAT BAC cre-recombinase driver lines to study the
858 functional organization of cerebral cortical and basal ganglia circuits. *Neuron* **80**, 1368-
859 1383 (2013).
- 860 24. Daigle TL, *et al.* A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced
861 Brain-Cell-Type Targeting and Functionality. *Cell* **174**, 465-480 e422 (2018).
- 862 25. Krishnamurthy A, *et al.* Engrailed transcription factors direct excitatory cerebellar neuron
863 diversity and survival. *bioRxiv*, (2023).
- 864 26. Gruver KMJ, J. W.; Fields, E.; Song, S.; Sjöström, P. J.; Watt, A. J. Structured connectivity
865 in the output of the cerebellar cortex. *bioRxiv*, (2023).
- 866 27. Badura A, *et al.* Normal cognitive and social development require posterior cerebellar
867 activity. *Elife* **7**, (2018).
- 868 28. Verpeut JL, *et al.* Cerebellar contributions to a brainwide network for flexible behavior in
869 mice. *Commun Biol* **6**, 605 (2023).
- 870 29. Wang X, Yu SY, Ren Z, De Zeeuw CI, Gao Z. A FN-MdV pathway and its role in cerebellar
871 multimodular control of sensorimotor behavior. *Nat Commun* **11**, 6050 (2020).
- 872 30. Ahmadzadeh E, *et al.* A collection of genetic mouse lines and related tools for inducible
873 and reversible intersectional mis-expression. *Development* **147**, (2020).
- 874 31. Leto K, *et al.* Consensus Paper: Cerebellar Development. *Cerebellum* **15**, 789-828 (2016).
- 875 32. Dietrichs E. Cerebellar cortical and nuclear afferents from the feline locus coeruleus
876 complex. *Neuroscience* **27**, 77-91 (1988).
- 877 33. Kabir ZD, *et al.* Rescue of impaired sociability and anxiety-like behavior in adult cacna1c-
878 deficient mice by pharmacologically targeting eIF2alpha. *Mol Psychiatry* **22**, 1096-1109
879 (2017).
- 880 34. Yang M, Silverman JL, Crawley JN. Automated three-chambered social approach task for
881 mice. *Curr Protoc Neurosci* **Chapter 8**, Unit 8 26 (2011).

- 882 35. Brown HD, Baker PM, Ragozzino ME. The parafascicular thalamic nucleus concomitantly
883 influences behavioral flexibility and dorsomedial striatal acetylcholine output in rats. *J*
884 *Neurosci* **30**, 14390-14398 (2010).
- 885 36. Kato S, *et al.* Action Selection and Flexible Switching Controlled by the Intralaminar
886 Thalamic Neurons. *Cell Rep* **22**, 2370-2382 (2018).
- 887 37. Melief EJ, *et al.* Loss of glutamate signaling from the thalamus to dorsal striatum impairs
888 motor function and slows the execution of learned behaviors. *NPJ Parkinsons Dis* **4**, 23
889 (2018).
- 890 38. Xiao L, Bornmann C, Hatstatt-Burkle L, Scheiffele P. Regulation of striatal cells and goal-
891 directed behavior by cerebellar outputs. *Nat Commun* **9**, 3133 (2018).
- 892 39. Arefin TM, *et al.* Towards reliable reconstruction of the mouse brain corticothalamic
893 connectivity using diffusion MRI. *Neuroimage* **273**, 120111 (2023).
- 894 40. Arefin TM, Lee CH, White JD, Zhang J, Kaffman A. Macroscopic Structural and
895 Connectome Mapping of the Mouse Brain Using Diffusion Magnetic Resonance Imaging.
896 *Bio Protoc* **11**, e4221 (2021).
- 897 41. Asemi-Rad A, Ghiyamihoor F, Consalez GG, Marzban H. Ablation of Projection
898 Glutamatergic Neurons in the Lateral Cerebellar Nuclei Alters Motor Coordination in
899 Vglut2-Cre+ Mice. *Cerebellum*, (2023).
- 900 42. Carlson ES, *et al.* Catecholaminergic Innervation of the Lateral Nucleus of the Cerebellum
901 Modulates Cognitive Behaviors. *J Neurosci* **41**, 3512-3530 (2021).
- 902 43. Dumas DB, Gornati SV, Adolfs Y, Shimogori T, Pasterkamp RJ, Hoebeek FE. Anatomical
903 Development of the Cerebellothalamic Tract in Embryonic Mice. *Cells* **11**, (2022).
- 904 44. Houck BD, Person AL. Cerebellar Premotor Output Neurons Collateralize to Innervate the
905 Cerebellar Cortex. *J Comp Neurol* **523**, 2254-2271 (2015).
- 906 45. Locke TM, *et al.* Dopamine D1 Receptor-Positive Neurons in the Lateral Nucleus of the
907 Cerebellum Contribute to Cognitive Behavior. *Biol Psychiatry* **84**, 401-412 (2018).

- 908 46. Low AYT, *et al.* Reverse-translational identification of a cerebellar satiation network.
909 *Nature* **600**, 269-273 (2021).
- 910 47. Low AYT, *et al.* Precision of Discrete and Rhythmic Forelimb Movements Requires a
911 Distinct Neuronal Subpopulation in the Interposed Anterior Nucleus. *Cell Rep* **22**, 2322-
912 2333 (2018).
- 913 48. Frontera JL, *et al.* Bidirectional control of fear memories by cerebellar neurons projecting
914 to the ventrolateral periaqueductal grey. *Nat Commun* **11**, 5207 (2020).
- 915 49. Frontera JL, *et al.* The cerebellum regulates fear extinction through thalamo-prefrontal
916 cortex interactions in male mice. *Nat Commun* **14**, 1508 (2023).
- 917 50. Pisano TJ, *et al.* Homologous organization of cerebellar pathways to sensory, motor, and
918 associative forebrain. *Cell Rep* **36**, 109721 (2021).
- 919 51. Liu J, *et al.* Striatal glutamate delta-1 receptor regulates behavioral flexibility and
920 thalamostriatal connectivity. *Neurobiol Dis* **137**, 104746 (2020).
- 921 52. Trinh MA, *et al.* The eIF2alpha kinase PERK limits the expression of hippocampal
922 metabotropic glutamate receptor-dependent long-term depression. *Learn Mem* **21**, 298-
923 304 (2014).
- 924 53. Bicks LK, Koike H, Akbarian S, Morishita H. Prefrontal Cortex and Social Cognition in
925 Mouse and Man. *Front Psychol* **6**, 1805 (2015).
- 926 54. Parnaudeau S, Bolkan SS, Kellendonk C. The Mediodorsal Thalamus: An Essential
927 Partner of the Prefrontal Cortex for Cognition. *Biol Psychiatry* **83**, 648-656 (2018).
- 928 55. Calhoon GG, Tye KM. Resolving the neural circuits of anxiety. *Nat Neurosci* **18**, 1394-
929 1404 (2015).
- 930 56. Kim H, Lim CS, Kaang BK. Neuronal mechanisms and circuits underlying repetitive
931 behaviors in mouse models of autism spectrum disorder. *Behav Brain Funct* **12**, 3 (2016).
- 932 57. Lalonde R, Strazielle C. Behavioral effects of neonatal lesions on the cerebellar system.
933 *Int J Dev Neurosci* **43**, 58-65 (2015).


- 934 58. Manto M, *et al.* Consensus paper: roles of the cerebellum in motor control--the diversity
935 of ideas on cerebellar involvement in movement. *Cerebellum* **11**, 457-487 (2012).
- 936 59. Tsai PT, *et al.* Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1
937 mutant mice. *Nature* **488**, 647-651 (2012).
- 938 60. van der Heijden ME, *et al.* Maturation of Purkinje cell firing properties relies on
939 neurogenesis of excitatory neurons. *Elife* **10**, (2021).
- 940 61. Prekop HT, *et al.* Sox14 Is Required for a Specific Subset of Cerebello-Olivary Projections.
941 *J Neurosci* **38**, 9539-9550 (2018).
- 942 62. Liang B, *et al.* Striatal direct pathway neurons play leading roles in accelerating rotarod
943 motor skill learning. *iScience* **25**, 104245 (2022).
- 944 63. Rose MF, Ahmad KA, Thaller C, Zoghbi HY. Excitatory neurons of the proprioceptive,
945 interoceptive, and arousal hindbrain networks share a developmental requirement for
946 Math1. *Proc Natl Acad Sci U S A* **106**, 22462-22467 (2009).
- 947 64. Cheng Y, *et al.* The Engrailed homeobox genes determine the different foliation patterns
948 in the vermis and hemispheres of the mammalian cerebellum. *Development* **137**, 519-529
949 (2010).
- 950 65. Joyner AL. Engrailed, Wnt and Pax genes regulate midbrain--hindbrain development.
951 *Trends Genet* **12**, 15-20 (1996).
- 952 66. Joyner AL, Herrup K, Auerbach BA, Davis CA, Rossant J. Subtle cerebellar phenotype in
953 mice homozygous for a targeted deletion of the En-2 homeobox. *Science* **251**, 1239-1243
954 (1991).
- 955 67. Kuemerle B, Zanjani H, Joyner A, Herrup K. Pattern deformities and cell loss in Engrailed-
956 2 mutant mice suggest two separate patterning events during cerebellar development. *J*
957 *Neurosci* **17**, 7881-7889 (1997).

- 958 68. Millen KJ, Hui CC, Joyner AL. A role for En-2 and other murine homologues of Drosophila
959 segment polarity genes in regulating positional information in the developing cerebellum.
960 *Development* **121**, 3935-3945 (1995).
- 961 69. Millen KJ, Wurst W, Herrup K, Joyner AL. Abnormal embryonic cerebellar development
962 and patterning of postnatal foliation in two mouse Engrailed-2 mutants. *Development* **120**,
963 695-706 (1994).
- 964 70. Orvis GD, *et al.* The engrailed homeobox genes are required in multiple cell lineages to
965 coordinate sequential formation of fissures and growth of the cerebellum. *Dev Biol* **367**,
966 25-39 (2012).
- 967 71. Sgaier SK, *et al.* Genetic subdivision of the tectum and cerebellum into functionally related
968 regions based on differential sensitivity to engrailed proteins. *Development* **134**, 2325-
969 2335 (2007).
- 970 72. Sillitoe RV, Stephen D, Lao Z, Joyner AL. Engrailed homeobox genes determine the
971 organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum. *J*
972 *Neurosci* **28**, 12150-12162 (2008).
- 973 73. Wurst W, Auerbach AB, Joyner AL. Multiple developmental defects in Engrailed-1 mutant
974 mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum.
975 *Development* **120**, 2065-2075 (1994).
- 976 74. LeDoux MS, Lorden JF, Ervin JM. Cerebellectomy eliminates the motor syndrome of the
977 genetically dystonic rat. *Exp Neurol* **120**, 302-310 (1993).
- 978 75. LeDoux MS, Lorden JF, Meinzen-Derr J. Selective elimination of cerebellar output in the
979 genetically dystonic rat. *Brain Res* **697**, 91-103 (1995).
- 980 76. Grusser C, Grusser-Cornehls U. Improvement in motor performance of Weaver mutant
981 mice following lesions of the cerebellum. *Behav Brain Res* **97**, 189-194 (1998).

- 982 77. Grusser-Cornehls U, Grusser C, Baurle J. Vermectomy enhances parvalbumin expression
983 and improves motor performance in weaver mutant mice: an animal model for cerebellar
984 ataxia. *Neuroscience* **91**, 315-326 (1999).
- 985 78. Badreddine N, *et al.* Spatiotemporal reorganization of corticostriatal networks encodes
986 motor skill learning. *Cell Rep* **39**, 110623 (2022).
- 987 79. Augustin SM, Loewinger GC, O'Neal TJ, Kravitz AV, Lovinger DM. Dopamine D2 receptor
988 signaling on iMSNs is required for initiation and vigor of learned actions.
989 *Neuropsychopharmacology* **45**, 2087-2097 (2020).
- 990 80. Augustin SM, Gracias AL, Luo G, Anumola RC, Lovinger DM. Striatonigral direct pathway
991 2-arachidonoylglycerol contributes to ethanol effects on synaptic transmission and
992 behavior. *Neuropsychopharmacology* **48**, 1941-1951 (2023).
- 993 81. Bailey KR, Mair RG. Lesions of specific and nonspecific thalamic nuclei affect prefrontal
994 cortex-dependent aspects of spatial working memory. *Behav Neurosci* **119**, 410-419
995 (2005).
- 996 82. Matei V, *et al.* Smaller inner ear sensory epithelia in Neurog 1 null mice are related to
997 earlier hair cell cycle exit. *Dev Dyn* **234**, 633-650 (2005).
- 998 83. Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA. Early restriction of peripheral and
999 proximal cell lineages during formation of the lung. *Proc Natl Acad Sci U S A* **99**, 10482-
1000 10487 (2002).
- 1001 84. Kimmel RA, Turnbull DH, Blanquet V, Wurst W, Loomis CA, Joyner AL. Two lineage
1002 boundaries coordinate vertebrate apical ectodermal ridge formation. *Genes Dev* **14**, 1377-
1003 1389 (2000).
- 1004 85. Bavley CC, *et al.* Rescue of Learning and Memory Deficits in the Human Nonsyndromic
1005 Intellectual Disability Cereblon Knock-Out Mouse Model by Targeting the AMP-Activated
1006 Protein Kinase-mTORC1 Translational Pathway. *J Neurosci* **38**, 2780-2795 (2018).

- 1007 86. Tsai PT, *et al.* Sensitive Periods for Cerebellar-Mediated Autistic-like Behaviors. *Cell Rep*
1008 **25**, 357-367 e354 (2018).
- 1009 87. Liu Y, McAfee SS, Van Der Heijden ME, Dhamala M, Sillitoe RV, Heck DH. Causal
1010 Evidence for a Role of Cerebellar Lobulus Simplex in Prefrontal-Hippocampal Interaction
1011 in Spatial Working Memory Decision-Making. *Cerebellum* **21**, 762-775 (2022).
- 1012 88. Van Der Heijden ME, Gill JS, Rey Hipolito AG, Salazar Leon LE, Sillitoe RV. Quantification
1013 of Behavioral Deficits in Developing Mice With Dystonic Behaviors. *Dystonia* **1**, (2022).
- 1014 89. Friard O, Gamba M. BORIS: a free, versatile open-source event-logging software for
1015 video/audio coding and live observations. *Methods in Ecology and Evolution* **7**, 1325-1330
1016 (2016).
- 1017 90. Johnson MA, *et al.* Chronic stress differentially alters mRNA expression of opioid peptides
1018 and receptors in the dorsal hippocampus of female and male rats. *J Comp Neurol* **529**,
1019 2636-2657 (2021).
- 1020 91. Blaess S, *et al.* Temporal-spatial changes in Sonic Hedgehog expression and signaling
1021 reveal different potentials of ventral mesencephalic progenitors to populate distinct ventral
1022 midbrain nuclei. *Neural Dev* **6**, 29 (2011).
- 1023 92. Schindelin J, *et al.* Fiji: an open-source platform for biological-image analysis. *Nat*
1024 *Methods* **9**, 676-682 (2012).
- 1025 93. Paxinos G, Watson C. *The rat brain in stereotaxic coordinates*, 6th edn. Academic
1026 Press/Elsevier (2007).
- 1027 94. Aggarwal M, Mori S, Shimogori T, Blackshaw S, Zhang J. Three-dimensional diffusion
1028 tensor microimaging for anatomical characterization of the mouse brain. *Magn Reson Med*
1029 **64**, 249-261 (2010).
- 1030 95. Jiang H, van Zijl PC, Kim J, Pearlson GD, Mori S. DtiStudio: resource program for diffusion
1031 tensor computation and fiber bundle tracking. *Comput Methods Programs Biomed* **81**,
1032 106-116 (2006).

- 1033 96. Wu D, Zhang J. In vivo mapping of macroscopic neuronal projections in the mouse
1034 hippocampus using high-resolution diffusion MRI. *Neuroimage* **125**, 84-93 (2016).
- 1035 97. White JD, *et al.* Early life stress causes sex-specific changes in adult fronto-limbic
1036 connectivity that differentially drive learning. *Elife* **9**, (2020).
- 1037 98. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural
1038 and functional systems. *Nat Rev Neurosci* **10**, 186-198 (2009).
- 1039 99. Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GRETNA: a graph theoretical network
1040 analysis toolbox for imaging connectomics. *Front Hum Neurosci* **9**, 386 (2015).
- 1041 100. Rubinov M, Sporns O. Weight-conserving characterization of complex functional brain
1042 networks. *Neuroimage* **56**, 2068-2079 (2011).
- 1043
- 1044



1045

1046 **Fig. 1 | Acute adult chemogenetic inhibition of MedP eCN impairs reversal learning and not**

1047 **motor behaviors.**

1048 **a**, Schematic representation of a lateral sagittal plane of the mouse cerebellum on the left with
1049 vertical lines (**i** and **ii**) indicating the location of the anterior and posterior coronal schematics
1050 shown to right.

1051 **b,c**, Representative coronal images of tdTomato expression in the anterior CN (**b**) and posterior
1052 (**c**) CN of *SepW1-Cre; Ai75D* mice. CN were subdivided into five subregions based on histological
1053 distinctions (Paxinos and Franklin, 2007) and MEIS2 immunostaining. Abbreviations:
1054 MedA=Anterior medial; MedP=Posterior medial; IntA=Anterior interposed; IntP=Posterior
1055 interposed; Lat=Lateral. Scale bars = 500 μ m.

1056 **d**, Quantification of tdTomato⁺ cells on every second coronal section of *SepW1-Cre; Ai75D* mice
1057 (n=4) in the lateral CN (Lat) and subregions of the intermediate (Int) and medial (Med) CN (n=4
1058 mice).

1059 **e**, Representative image of tdTomato (magenta) and MEIS2 (green) co-expressing eCN in
1060 *SepW1-Cre; Ai75D* mice. Scale bars = 50 μ m.

1061 **f**, Quantification of tdTomato⁺ cells that co-express MEIS2 and the reverse in *SepW1-Cre; Ai75D*
1062 mice (n=4 mice).

1063 **g**, Schematic of viral injection to express mCherry (control) or hM4Di-mCherry (MedP-hM4Di) in
1064 adult MedP eCN. Dashed line indicates region shown in (**i**).

1065 **h**, Representative images of MedP eCN mCherry⁺ axon terminals (black) in four thalamic nuclei
1066 of control mice. Fluorescent images were inverted using the look up table in Fiji. Abbreviations:
1067 MD=mediodorsal; CL=centrolateral; VM=ventromedial; PF=parafascicular. Scale bars = 250 μ m.

1068 **i**, Representative images of viral mCherry expression in MedP eCN in control (top, AAV-DIO-
1069 mCherry) and MedP-hM4Di (bottom, AAV-DIO-hM4Di-mCherry) mice. Scale bars = 250 μ m.

1070 **j**, Experimental timeline of surgery, CNO injection and behavioral tests.

1071 **k**, (left) Representative images of footprints from control and MedP-hM4Di mice. (right)
1072 quantification of stride, stance, and sway (n=11 per group). Multiple Mann-Whitney *U* tests for

1073 effect of genotype on stride ($U = 48$, $P = 0.4385$), stance ($U = 34$, $P = 0.0843$) and sway ($U = 58$,
1074 $P = 0.8851$).

1075 **l**, Total distance travelled during basal locomotion ($n=11$ per group; $t_{20} = 0.3910$, $P = 0.7000$).

1076 **m**, Latency to fall during the accelerating rotarod test (MedP-hM4Di: $n=11$, control: $n=10$).

1077 Repeated measure two-way ANOVA: main effect of time ($F_{4,750,90,25} = 27.51$, $P < 0.0001$), but not
1078 of chemogenetics ($F_{1,19} = 0.9367$, $P = 0.3453$) or interaction ($F_{5,152} = 0.3699$, $P = 0.9351$).


1079 **n**, Forelimb grip strength normalized to body weight (MedP-hM4Di: $n=11$, control: $n=10$; two-tailed
1080 unpaired t-test: $t_{19} = 1.677$, $P = 0.1099$).

1081 **o**, Total number of correct trials during the water Y-maze test (MedP-hM4Di: $n=10$, control: $n=9$).

1082 Repeated measure two-way ANOVA: main effect of time ($F_{5,85} = 27.65$, $P < 0.0001$) and
1083 chemogenetics ($F_{1,17} = 9.855$, $P = 0.006$), but not of interaction ($F_{5,85} = 2.257$, $P = 0.0559$); with
1084 post hoc two-tailed t-tests with Šídák correction for effect of chemogenetics on Reversal Day 1
1085 ($t_{102} = 3.386$, $P = 0.006$), and not other comparisons ($P \geq 0.05$).

1086 **p**, Percentage spontaneous alternations in the Y-maze (MedP-hM4Di: $n=10$, control: $n=9$; two-
1087 tailed unpaired t-test: $t_{17} = 0.9024$, $P = 0.3794$).

1088 **ns**, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1089

1090 **Fig. 2 | Generation of mice lacking the MedP eCN by conditional knockout of *En1/2*.**

1091 **a**, Quantification of eCN number (large (100-600 μm^2) NeuN+ cells) along the medial-lateral axis
 1092 in adult *SepW1-En1/2* CKOs (n=5) and littermate controls (n=6). Ordinary two-way ANOVA: main
 1093 effect of mediolateral distance ($F_{19,180} = 24.02$, $P < 0.0001$), genotype ($F_{1,180} = 86.54$, $P < 0.0001$),
 1094 and interaction ($F_{19,180} = 2.449$, $P < 0.0001$); with post hoc two-tailed t-tests with uncorrected
 1095 Fisher's LSD for effect of genotype for bin 5-10% ($t_{180} = 3.180$, $P = 0.0017$), bins 10-30% (list of t
 1096 value for each bin: $t_{180} = 4.858, 5.738, 4.218, 4.028$; all P values: $P < 0.0001$), bin 30-35% ($t_{180} =$
 1097 2.703 , $P = 0.0075$), bin 35-40% ($t_{180} = 2.238$, $P = 0.0265$), bin 75-80% ($t_{180} = 2.002$, $P = 0.0468$),
 1098 but not other comparisons ($P \geq 0.05$). Abbreviations: Med=medial; Int=interposed; Lat=lateral.

1099 **b**, Representative coronal images of MEIS2 labeling in the anterior and posterior CN of an adult
 1100 *SepW1-En1/2* CKO and littermate control as indicated. Scale bars = 500 μm .

1101 **c**, Representative images of H&E labeled sagittal sections of vermis (Ver), paravermis (pVer),
1102 and hemisphere (Hemi) from a *SepW1-En1/2* CKO and littermate control. Scale bars = 1 mm.

1103 **d**, Quantification of total cerebellar (CB) area of *SepW1-En1/2* CKOs (n=5) compared to littermate
1104 controls (n=6) in the vermis, paravermis and hemispheres. Ordinary two-way ANOVA: main effect
1105 of region ($F_{2,27} = 42.06$, $P < 0.0001$) and genotype ($F_{1,27} = 37.13$, $P < 0.0001$), and interaction
1106 ($F_{2,27} = 5.825$, $P = 0.0079$); with post hoc two-tailed t-tests with uncorrected Fisher's LSD for effect
1107 of genotype for vermis ($t_{27} = 6.292$, $P < 0.0001$), paravermis ($t_{27} = 2.359$, $P = 0.0258$), and
1108 hemisphere ($P = 0.0678$).

1109 **e**, Quantification of molecular layer (ML) area as a percent of total CB area in *SepW1-En1/2* CKOs
1110 (n=5) compared to littermate controls (n=6). Ordinary two-way ANOVA: main effect of region ($F_{2,27}$
1111 $= 32.11$, $P < 0.0001$), genotype ($F_{1,27} = 5.236$, $P = 0.0302$), but not of interaction ($P = 0.5866$).

1112 **f**, Quantification of internal granule cell layer (IGL) area as a percent of total CB area in *SepW1-*
1113 *En1/2* CKOs (n=5) compared to littermate controls (n=6). Ordinary two-way ANOVA: main effect
1114 of region ($F_{2,27} = 82.04$, $P < 0.0001$), but not of genotype ($P = 0.6943$) or interaction ($P = 0.8641$).


1115 **g**, Quantification of Purkinje cell (PC) density in *SepW1-En1/2* CKOs (n=5) compared to littermate
1116 controls (n=6). Ordinary two-way ANOVA: main effect of region ($F_{2,18} = 18.34$, $P < 0.0001$), but
1117 not of genotype ($P = 0.4167$) or interaction ($P = 0.7216$).

1118 **h**, Quantification of PV+ MLI density in *SepW1-En1/2* CKOs (n=5) compared to littermate controls
1119 (n=6). Ordinary two-way ANOVA: main effect of region ($F_{2,27} = 16.66$, $P < 0.0001$), but not of
1120 genotype ($P = 0.8926$) or interaction ($P = 0.4617$).

1121 **i**, Quantification of granule cell (GC) density in the IGL of *SepW1-En1/2* CKOs (n=5) compared
1122 to littermate controls (n=6). Ordinary two-way ANOVA: no main effect of region ($P = 0.9948$),
1123 genotype ($P = 0.8945$) or interaction ($P = 0.9502$).

1124 **j**, Quantification of the estimated ratio of the number of PCs to PV+ MLIs in *SepW1-En1/2* CKOs
1125 (n=5) compared to littermate controls (n=6). Ordinary two-way ANOVA: no significant main effect
1126 of region ($P = 0.3807$), genotype ($P = 0.7618$) or interaction ($P = 0.7701$).

1127 **k**, Quantification of the estimated ratio of the number of PCs to GCs in *SepW1-En1/2* CKOs (n=5)
1128 compared to littermate controls (n=6). Ordinary two-way ANOVA: main effect of region ($F_{1,27} =$
1129 4.769, $P = 0.0168$), but no main effect of genotype ($P = 0.7368$) or interaction ($P = 0.2521$).
1130 **l**, Quantification of the estimated ratio of the number of PV+ MLIs to GCs in *SepW1-En1/2* CKOs
1131 (n=5) compared to littermate controls (n=6). Ordinary two-way ANOVA: main effect of region ($F_{1,27}$
1132 = 4.638, $P = 0.0186$), but not of genotype ($P = 0.9195$) or interaction ($P = 0.9841$).
1133 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1134

1135 **Fig. 3 | Mice lacking MedP eCN have normal reversal learning as well as motor behaviors.**

1136 **a**, (left) Representative images of footprints from one *SepW1-En1/2* CKO and littermate control.
 1137 (right) Quantification of stride, stance, and sway (*SepW1-En1/2* CKOs: n=27, littermate controls:
 1138 n=22). Multiple Mann-Whitney *U* tests showing effect of genotype on sway ($U = 188, P = 0.0276$),
 1139 but not stride ($U = 234, P = 0.2087$) or stance ($U = 279, P = 0.7235$).

1140 **b**, Total distance travelled during basal locomotion (*SepW1-En1/2* CKOs: n=24, littermate
 1141 controls: n=27; Mann-Whitney *U* test: $U = 264, P = 0.2640$).

1142 **c**, Latency to fall during the accelerating rotarod test (*SepW1-En1/2* CKOs: n=23, littermate
 1143 controls: n=27). Repeated measure two-way ANOVA: main effect of time ($F_{4,590,220.3} = 69.92, P <$
 1144 0.0001), but not of genotype ($F_{1,48} = 0.3434, P = 0.5606$) or interaction ($F_{8,384} = 0.4280, P < 0.9041$).

1145 **d**, Forelimb grip strength coronal normalized to body weight (*SepW1-En1/2* CKOs: n=23,
 1146 littermate controls: n=27; two-tailed unpaired t-test: $t_{48} = 1.1018, P = 0.6689$).

1147 **e**, Total number of correct trials during the water Y-maze test (*SepW1-En1/2* CKOs: n=18,
 1148 littermate controls: n=23). Repeated measure two-way ANOVA: main effect of time ($F_{3,132,122.1} =$


1149 38.86, $P < 0.0001$), but not of genotype ($F_{1,39} = 0.5638$, $P = 0.4572$) or interaction ($F_{5,195} = 1.492$,
1150 $P = 0.1941$).

1151 **f**, Percentage of spontaneous alternations in the Y-maze (*SepW1-En1/2* CKOs: $n=23$, littermate
1152 controls: $n=26$); two-tailed unpaired t-test: $t_{47} = 0.8600$, $P = 0.3942$).

1153 **g**, Latency to right onto four paws at P7 (*SepW1-En1/2* CKOs: $n=17$, littermate controls: $n=13$;
1154 two-tailed unpaired t-test: $t_{28} = 0.1171$, $P = 0.9076$).

1155 **h**, Latency to turn upward on a negative slope at P7 and P11 (*SepW1-En1/2* CKOs: $n=17$,
1156 littermate controls: $n=13$). Multiple Mann-Whitney U tests with Holm-Šidák correction for effect of
1157 genotype at P7 ($U = 79$, $P = 0.3562$) and at P11 ($U = 92.50$, $P = 0.4634$).

1158 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1159

1160 **Fig. 4 | Generation of mice in which all embryonic eCN are ablated using Diphtheria toxin.**

1161 **a**, Intersectional approach to pharmacogenetically ablate the embryonic eCN. A doxycycline
 1162 (Dox)-controlled and recombinase activated gene overexpression allele (DRAGON) for
 1163 attenuated diphtheria toxin fragment A (DTA) (*Igs7*^{DRAGON-DTA}) combined with an *Atoh1*-*tTA*
 1164 transgene and *En1*^{Cre} knock-in allele results in embryonic killing of eCN when Dox is administered
 1165 starting at E13.5 via expression of DTA. The genotypes of littermate controls are *Atoh1*-*tTA* or
 1166 *En1*^{Cre} along with the *Igs7*^{DRAGON-DTA} allele.

1167 **b**, Representative images of sagittal sections stained for MEIS2 (white) in medial and lateral
1168 cerebellum of an E17.5 *eCN-DTA* and littermate control. Scale bars = 250 μ m.

1169 **c**, Quantification of total number of MEIS2+ cells on every 10th sagittal section of E17.5 *eCN-DTA*
1170 mice (n=3) compared to littermate controls (n=3) (two-tailed unpaired t-test: $t_4 = 15.62$, $P < 0.0001$).

1171 **d**, Mediolateral distribution of NeuN+ large cells (100-600 μ m²) in adult *eCN-DTA* mice (n=5)
1172 compared to littermate controls (n=6). Repeated measure two-way ANOVA: main effect of
1173 mediolateral distance ($F_{19,180} = 6.669$, $P < 0.0001$), genotype ($F_{1,180} = 359.5$, $P < 0.0001$), and
1174 interaction ($F_{19,180} = 5.745$, $P < 0.0001$); with post hoc two-tailed t-tests with uncorrected Fisher's
1175 LSD for effect of genotype show significance for bin 10-15% ($t_{180} = 3.327$, $P = 0.0163$), bin 15-20%
1176 ($t_{180} = 4.439$, $P = 0.0011$), bins 20-85% (list of t value for each bin: $t_{180} = 4.349$, 4.684, 5.539,
1177 5.676, 6.22, 4.587, 5.939, 6.153, 6.76, 6.181, 7.551, 6.744, 4.676; all P values: $P < 0.0001$), bin
1178 85-90% ($t_{180} = 2.229$, $P = 0.027$), but not other comparisons ($P \geq 0.05$). Abbreviations:
1179 Med=medial; Int=interposed; Lat=lateral.

1180 **e**, Representative images of RNA *in situ* analysis of coronal sections for *Slc17a6* expression in
1181 the CN of *eCN-DTA* mice and littermate controls. Dotted outlines indicate the CN subregions.
1182 Images are single channel inverted using lookup table in Fiji. Scale bars = 500 μ m.

1183 **f**, Representative images of triple RNA *in situ* of coronal sections in the medial CN showing some
1184 neurons co-express *Slc32a1*, *Slc17a6*, and *Slc6a5*. Arrowhead and asterisk indicate neurons
1185 expressing only *Slc32a1* or *Slc17a6* in controls, respectively. Scale bars = 50 μ m.

1186 **g**, Representative images of H&E labeled vermis (Ver), paravermis (pVer), and hemisphere (Hemi)
1187 sagittal sections from an *eCN-DTA* and littermate control. Scale bars = 1 mm.

1188 **h**, Quantification of total cerebellar (CB) area in *eCN-DTA* mice (n=5) and littermate controls (n=6)
1189 in the vermis, paravermis and hemispheres. Ordinary two-way ANOVA: main effect of region ($F_{2,27}$
1190 = 32.08, $P < 0.0001$) and genotype ($F_{1,27} = 89.64$, $P < 0.0001$), but not of interaction ($P = 0.9488$);
1191 with post hoc two-tailed t-tests with uncorrected Fisher's LSD for effect of genotype for vermis (t_{27}

1192 = 5.260, $P < 0.0001$), paravermis ($t_{27} = 5.425$, $P < 0.0001$), and hemisphere ($t_{27} = 5.713$, $P <$
1193 0.0001).

1194 **i**, Quantification of molecular layer (ML) area as a percent of total CB area in *eCN-DTA* mice ($n=5$)
1195 compared to littermate controls ($n=6$). Ordinary two-way ANOVA: main effect of region ($F_{2,27} =$
1196 37.84 , $P < 0.0001$), but not of genotype ($P = 0.3540$) or interaction ($P = 0.1589$).

1197 **j**, Quantification of IGL area as a percent of total CB area in *eCN-DTA* mice ($n=5$) compared to
1198 littermate controls ($n=6$). Ordinary two-way ANOVA: main effect of region ($F_{2,27} = 7.249$, $P = 0.003$),
1199 but not of genotype ($P = 0.0545$) or interaction ($P = 0.1911$); with post hoc two-tailed t-tests with
1200 uncorrected Fisher's LSD for effect of genotype for hemisphere ($t_{27} = 2.220$, $P = 0.0350$), but not
1201 other comparisons ($P \geq 0.05$).

1202 **k**, Quantification of PC density in *eCN-DTA* mice ($n=5$) compared to littermate controls ($n=6$).
1203 Ordinary two-way ANOVA: main effect of region ($F_{2,18} = 10.23$, $P = 0.0011$), but not of genotype
1204 ($P = 0.1660$) or interaction ($P = 0.2277$).


1205 **l**, Quantification of PV+ MLI density in *eCN-DTA* mice ($n=5$) compared to littermate controls ($n=6$).
1206 Ordinary two-way ANOVA: no main effect of region ($P = 0.2153$), genotype ($P = 0.1660$) or
1207 interaction ($P = 0.2277$).

1208 **m**, Quantification of GC density in *eCN-DTA* mice ($n=5$) compared to littermate controls ($n=6$).
1209 Ordinary two-way ANOVA: main effect of region ($F_{2,18} = 10.08$, $P = 0.0012$), but not of genotype
1210 ($P = 0.6051$) or interaction ($P = 0.9220$).

1211 **n**, Quantification of the estimated ratio of the number of PCs to PV+ MLIs in *eCN-DTA* mice ($n=5$)
1212 compared to littermate controls ($n=6$). Ordinary two-way ANOVA: no significant main effect of
1213 region ($P = 0.4484$), genotype ($P = 0.2061$) or interaction ($P = 0.5916$).

1214 **o**, Quantification of the estimated ratio of the number of PCs to GCs in *eCN-DTA* mice ($n=5$)
1215 compared to littermate controls ($n=6$). Ordinary two-way ANOVA: main effect of genotype ($F_{1,27} =$
1216 7.013 , $P = 0.0134$), but not of region ($P = 0.0913$) or interaction ($P = 0.7645$).

1217 **p**, Quantification of the estimated ratio of the number of PV+ MLIs to GCs in *eCN-DTA* mice (n=5)
1218 compared to littermate controls (n=6). Ordinary two-way ANOVA: no significant main effect of
1219 region (P = 0.0680), genotype (P = 0.4415) or interaction (P = 0.6184).
1220 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1221


1222 **Fig. 5 | Loss of all eCN impairs motor coordination, but not motor learning and non-motor**
 1223 **behaviors.**

1224 **a**, Latency to right onto four paws at P7 (eCN-DTA mice: n=15, littermate controls: n=43; Mann-
 1225 Whitney *U* test: $U = 226$, $P = 0.0436$).

1226 **b**, Latency to turn upward on a negative slope at P7 and P11 (eCN-DTA mice: n=15, littermate
 1227 controls: n=43). Multiple Mann-Whitney *U* tests with Holm-Šídák correction for effect of genotype
 1228 at P7 ($U = 109$, $P < 0.0001$) and at P11 ($U = 89$, $P < 0.0001$).

1229 **c**, (left) Representative images of footprints from an *eCN-DTA* and littermate control. (right)
1230 Quantification of stride, stance, and sway (*eCN-DTA* mice: n=16, littermate controls: n=15).
1231 Multiple Mann-Whitney *U* tests for effect of genotype on stride ($U = 33$, $P = 0.00028$) and sway
1232 ($U = 32$, $P = 0.00023$), but not stance ($U = 113.5$, $P = 0.8073$).
1233 **d**, Total distance travelled during basal locomotion (*eCN-DTA* mice: n=16, littermate controls:
1234 n=15; two-tailed unpaired t-test: $t_{29} = 2.865$, $P = 0.0077$).
1235 **e**, Latency to fall in the accelerating rotarod test (*eCN-DTA* mice: n=15; littermate controls: n=15).
1236 Repeated measure two-way ANOVA: main effect of time ($F_{3,426,95.92} = 34.31$, $P < 0.0001$), but not
1237 of genotype ($P = 0.3873$) or interaction ($P = 0.6987$).
1238 **f**, Forelimb grip strength normalized to body weight (*eCN-DTA* mice: n=16, littermate controls:
1239 n=15; two-tailed unpaired t-test: $t_{28} = 1.684$, $P = 0.1033$).
1240 **g**, Total number of correct trials during the water Y-maze test (*eCN-DTA* mice: n=15, littermate
1241 controls: n=12). Repeated measure two-way ANOVA: main effect of time ($F_{1,667,41.67} = 17.92$, $P <$
1242 0.0001) and genotype ($F_{1,25} = 4.898$, $P = 0.0362$), but not of interaction ($P = 0.9183$); with post
1243 hoc two-tailed t-tests with Šídák correction for effect of genotype all being $P \geq 0.05$.
1244 **h**, Percentage of spontaneous alternations in the Y-maze (*eCN-DTA* mice: n=15, littermate
1245 controls: n=14; Mann-Whitney *U* test: $U = 76.50$, $P = 0.2209$). Chance level performance is 50%
1246 (dotted line).
1247 **i**, Percentage of spontaneous alternations in the plus-maze (*eCN-DTA* mice: n=16, littermate
1248 control: n=15; two-tailed unpaired t-test: $t_{29} = 0.4309$, $P = 0.6698$). Chance level performance is
1249 22.2% (dotted line).
1250 **j**, Social preference (percent time nose spent within novel mouse contact zone) during the three-
1251 chamber social approach test (*eCN-DTA* mice: n=16, littermate controls: n=15; Mann-Whitney *U*
1252 test: $U = 102$, $P = 0.4945$). Wilcoxon test against a null hypothesis (50%) in *eCN-DTA* mice ($W =$
1253 122 , $P = 0.0006$) and littermate controls ($W = 116$, $P = 0.0002$).

- 1254 **k**, Percentage of time spent in the open arms of an elevated plus maze (*eCN-DTA* mice: n=16,
1255 littermate controls: n=14; Mann-Whitney *U* test: $U = 74$, $P = 0.1179$).
- 1256 **l**, Total time spent self-grooming (*eCN-DTA* mice: n=16, littermate controls: n=15; Mann-Whitney
1257 *U* test: $U = 92$, $P = 0.2770$).
- 1258 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1259

1260 **Fig. 6 | Loss of *En1/2* in all eCN impairs motor coordination and learning, cognitive**
 1261 **flexibility, and spatial working memory.**

1262 **a**, Latency to right onto four paws at P7 (*Atoh1-En1/2* CKOs: n=19, littermate controls: n=22;
 1263 Mann-Whitney *U* test: $U = 192.5$, $P = 0.6741$).

1264 **b**, Latency to turn upward on a negative slope at P7 and P11 (*Atoh1-En1/2* CKOs: n=19, littermate
 1265 controls: n=22). Multiple Mann-Whitney *U* tests with Holm-Šidák correction for effect of genotype
 1266 at P7 ($U = 128$, $P = 0.0245$) and P11 ($U = 114.5$, $P = 0.033$).

1267 **c**, (left) Representative images of footprints from an *Atoh1-En1/2* CKO and littermate control.
1268 (right) Quantification of stride, stance, and sway (*Atoh1-En1/2* CKOs: n=28, littermate controls:
1269 n=30). Multiple Mann-Whitney *U* tests for effect of genotype on stride ($U = 237$, $P = 0.0039$) and
1270 sway ($U = 292.5$, $P = 0.047$), but not stance ($U = 312$, $P = 0.0936$).

1271 **d**, Total distance travelled during basal locomotion (*Atoh1-En1/2* CKOs: n=33, littermate controls:
1272 n=35; two-tailed unpaired t-test: $t_{66} = 3.931$, $P = 0.0002$).

1273 **e**, Latency to fall in the accelerating rotarod test (*Atoh1-En1/2* CKOs: n=32, littermate controls:
1274 n=30). Repeated measure two-way ANOVA: main effect of time ($F_{5.648,338.9} = 90.56$, $P < 0.0001$),
1275 genotype ($F_{1,60} = 7.791$, $P = 0.0070$), and interaction ($F_{8,480} = 5.827$, $P < 0.0001$); with post hoc
1276 two-tailed t-tests with Šídák correction for effect of genotype on day 2-trial 3 ($t_{59.83} = 3.721$, $P =$
1277 0.0040), day 3-trial 1 ($t_{55.69} = 3.019$, $P = 0.0338$), day 3-trial 2 ($t_{55.46} = 4.502$, $P = 0.0003$), day 3-
1278 trial 3 ($t_{57.98} = 4.416$, $P = 0.0004$), and other comparisons ($P \geq 0.05$).

1279 **f**, Forelimb grip strength normalized to body weight (*Atoh1-En1/2* CKOs: n=32, littermate controls:
1280 n=30; two-tailed unpaired t-test: $t_{60} = 0.4298$, $P = 0.6689$).

1281 **g**, Total number of correct trials during the water Y-maze test (*Atoh1-En1/2* CKOs: n=31,
1282 littermate controls: n=35). Repeated measure two-way ANOVA: main effect of time ($F_{3.003,192.2} =$
1283 118.4 , $P < 0.0001$), genotype ($F_{1,64} = 21.47$, $P < 0.0001$), and interaction ($F_{5,320} = 5.101$, $P =$
1284 0.0002); with post hoc two-tailed t-tests with Šídák correction for effect of genotype on Acquisition
1285 Day 1 ($t_{42.50} = 3.583$, $P = 0.0052$), Reversal Day 1 ($t_{52.14} = 3.821$, $P = 0.0021$), and no other
1286 comparisons ($P \geq 0.05$).

1287 **h**, Percentage of spontaneous alternations in the Y-maze (n=35 per genotype; two-tailed unpaired
1288 t-test: $t_{68} = 0.3622$, $P = 0.7183$). Chance level performance is 50% (dotted line).


1289 **i**, Percentage of spontaneous alternations in the plus-maze (n=22 per genotype; two-tailed
1290 unpaired t-test: $t_{42} = 2.486$, $P = 0.0170$). Chance level performance is 22.2% (dotted line).

1291 **j**, Social preference (percent time nose spent within novel mouse contact zone) during the three-
1292 chamber social approach test (*Atoh1-En1/2* CKOs: n=38, littermate controls: n=40; Mann-
1293 Whitney *U* test: $U = 723$, $P = 0.7167$). Wilcoxon test against a null hypothesis (50%) in *Atoh1-*
1294 *En1/2* CKOs ($W = 605$, $P < 0.0001$) and littermate controls ($W = 820$, $P < 0.0001$).

1295 **k**, Percentage of time spent in the open arms of an elevated plus maze (*Atoh1-En1/2* CKOs: n=46,
1296 littermate control: n=47; Mann-Whitney *U* test: $U = 923$, $P = 0.2266$).

1297 **j**, Total time spent self-grooming (n=34 per genotype; Mann-Whitney *U* test: $U = 455$, $P = 0.1336$).

1298 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1300 **Fig. 7 | *Atoh1-En1/2* CKOs have reduced cerebellothalamic projections, but no ectopic**
1301 **cerebellothalamic projections.**

1302 **a**, Schematic of anterograde tracing of MedA CN cells in adult *Atoh1-En1/2* CKOs and littermate
1303 controls.

1304 **b**, Representative images of coronal sections showing injection site and mCherry+ axon terminals
1305 (brown) in various thalamic regions from an *Atoh1-En1/2* CKO and littermate control. Scale bar:
1306 injection site = 1 mm and mCherry images = 250 μ m.

1307 **c**, Summary of mCherry+ axon terminals observed in thalamic nuclei of *Atoh1-En1/2* CKOs (blue)
1308 versus littermate controls (dark grey) on three representative coronal planes adapted from Allen
1309 Brain Atlas. Blue indicates reduced density.

1310 **d**, Schematic of anterograde tracing of anterior interposed CN (IntA) cells in adult *Atoh1-En1/2*
1311 CKOs and littermate controls.

1312 **e**, Representative images of coronal sections showing injection site and biotinylated dextran
1313 amine (BDA)+ axon terminals (brown) in various thalamic regions from an *Atoh1-En1/2* CKO and
1314 littermate control. Scale bar: injection site = 1 mm and BDA images = 250 μ m.

1315 **f**, Summary of BDA+ axon terminals observed in thalamic nuclei of *Atoh1-En1/2* CKOs (blue) and
1316 littermate controls (dark grey) versus on three representative coronal planes adapted from Allen
1317 Brain Atlas. Blue indicates reduced density.


1318 **g**, (top) Schematic of retrograde tracing in adult *Atoh1-En1/2* CKOs and littermate controls.

1319 **h,i**, Representative images of the injection site of Fluoro-Ruby (red) and Hoechst (blue) in
1320 centrolateral thalamus (CL, **h**) and parafascicular thalamus (PF, **i**). Scale bars = 1 mm.

1321 **j**, Quantification of Fluoro-Ruby+ cells in CN subregions that are retrogradely labeled from CL
1322 injection. Multiple Mann-Whitney *U* tests with Holm-Šídák correction for effect of genotype on
1323 MedP ($U = 0$, $P = 0.0126$) and IntP ($U = 0$, $P = 0.0126$), but not on MedA ($U = 15.5$, $P = 0.9400$),
1324 IntA ($U = 11$, $P = 0.6882$), and Lat ($U = 15$, $P = 0.9400$).

1325 **k**, Quantification of Fluoro-Ruby+ cells in CN subregions that are retrogradely labeled from PF
1326 injection. Multiple Mann-Whitney *U* tests with Holm-Šídák correction for effect of genotype on
1327 MedP ($U = 0$, $P = 0.0390$) and IntP ($U = 0$, $P = 0.0390$), but not on MedA ($U = 3.5$, $P = 0.2516$),
1328 IntA ($U = 1$, $P = 0.0922$), and Lat ($U = 10$, $P > 0.9999$).

1329 Abbreviations: AD=Anterodorsal nucleus; AM=Anteromedial nucleus; AV=Anteroventral nucleus
1330 of thalamus; CL=Central lateral nucleus; CM=Central medial nucleus; IAD=Interanterodorsal
1331 nucleus; IAM=Interanteromedial nucleus; IMD=Intermediodorsal nucleus; LD=Lateral dorsal
1332 nucleus of thalamus; LGv=Ventral part of the lateral geniculate complex; LP=Lateral posterior
1333 nucleus; MD=Mediodorsal nucleus of thalamus; PCN=Paracentral nucleus; PF=Parafascicular
1334 nucleus; PO=Posterior complex; PT=Parataenial nucleus; PVT=Paraventricular nucleus;
1335 RE=Nucleus of reuniens; RH=Rhomboid nucleus; RT=Reticular nucleus; SMT=Submedial
1336 nucleus; SPFm=Subparafascicular nucleus, magnocellular part; VAL=Ventral anterior-lateral
1337 complex; VM=Ventral medial nucleus; LGd=Dorsal part of the lateral geniculate complex;
1338 VPM=Ventral posteromedial nucleus; VPL=Ventral posterolateral nucleus;
1339 SPA=Subparafascicular area; VPMpc=Ventral posteromedial nucleus, parvicellular part;
1340 VPLpc=Ventral posterolateral nucleus, parvicellular part. ns, not significant: $P \geq 0.05$. Data are
1341 presented as mean values \pm SEM.



1342

1343 **Fig 8 | Diffusion MRI shows *Atoh1-En1/2* CKOs have connectivity changes outside the**

1344 **cerebellum that are distinct from *eCN-DTA* mice.**

1345 **a**, Quantification of cerebellar (CB) volume in *Atoh1-En1/2* CKOs (n=12) compared to littermate
1346 controls (n=13) (two-tailed unpaired t-test: $t_{23} = 11.15$, $P < 0.0001$).

1347 **b**, Quantification of regional volumes normalized to forebrain plus midbrain combined volume in
1348 *Atoh1-En1/2* CKOs (n=12) compared to littermate controls (n=13). Two-tailed unpaired t-tests to
1349 test for effect of genotype on MB ($t_{23} = 2.834$, $P = 0.0094$) and other comparisons $P \geq 0.05$.

1350 **c**, Schematic representation of global connectivity in *Atoh1-En1/2* CKOs compared to littermate
1351 controls. Black lines indicate no significant difference, red lines indicate reduced connectivity in
1352 *Atoh1-En1/2* CKOs and blue lines indicate increased connectivity in *Atoh1-En1/2* CKOs
1353 compared to littermate controls (two-tailed unpaired t-tests with Welch's correction).

1354 **d**, Quantification of global efficiency (Geff; *Atoh1-En1/2* CKOs: n=12, littermate controls: n=13;
1355 two-tailed unpaired t-test: $t_{23} = 7.876$, $P < 0.0001$).

1356 **e**, Quantification of small worldness (SW; *Atoh1-En1/2* CKOs: n=12, littermate controls: n=13;
1357 two-tailed unpaired t-test: $t_{23} = 3.913$, $P = 0.0007$).

1358 **f-j**, Representative images of ILM-SS (**f**), ILM-MO (**g**), ILM-DS (**h**), SS-DS (**i**), MO-DS (**j**)
1359 tractographies in right hemisphere of one *Atoh1-En1/2* CKO and littermate control. Target regions
1360 are outlined in dotted lines. The color of streamlines indicates their orientations, as indicated by
1361 the colored arrows on the right. Abbreviations: AP=anteroposterior; ML=mediolateral;
1362 DV=dorsoventral.

1363 **k-o**, Quantification of average (left plus right hemispheres) of ILM-SS tractography (**k**, two-tailed
1364 unpaired t-test: $t_{23} = 3.225$, $P = 0.0038$), ILM-MO tractography (**l**, two-tailed unpaired t-test: $t_{23} =$
1365 1.701 , $P = 0.1024$), ILM-DS tractography (**m**, two-tailed unpaired t-test: $t_{23} = 2.902$, $P = 0.0080$),
1366 SS-DS tractography (**n**, two-tailed unpaired t-test: $t_{23} = 4.813$, $P < 0.0001$), and MO-DS
1367 tractography (**o**, two-tailed unpaired t-test: $t_{23} = 2.515$, $P = 0.0194$) in *Atoh1-En1/2* CKO compared
1368 to littermate controls (*Atoh1-En1/2* CKOs: n=12, littermate controls: n=13).

1369 **p**, Quantification of cerebellar (CB) volume in *eCN-DTA* mice compared to littermate controls (n=5
1370 per genotype; two-tailed unpaired t-test: $t_8 = 4.295$, $P = 0.0026$).

1371 **q**, Quantification of regional volume normalized to forebrain plus midbrain combined volume in
1372 *eCN-DTA* mice (n=5) compared to littermate controls (n=5). Two-tailed unpaired t-tests to test for
1373 effect of genotype on CTX ($t_8 = 5.876$, $P = 0.0004$) and other comparisons $P \geq 0.05$.


1374 **r**, Schematic representation of global connectivity for *eCN-DTA* mice compared to littermate
1375 controls. Black lines indicate no significant difference and red lines indicate reduced connectivity
1376 in *eCN-DTA* mice compared to littermate controls (two-tailed unpaired t-tests with Welch's
1377 correction).

1378 **s**, Quantification of global efficiency (Geff; n=5 per genotype; two-tailed unpaired t-test: $t_8 = 2.535$,
1379 $P = 0.035$).

1380 **t**, Quantification of small worldness (SW; n=5 per genotype; two-tailed unpaired t-test: $t_8 = 1.591$,
1381 $P = 0.1503$).

1382 **u-y**, Quantification of average (left and right hemispheres) ILM-SS tractography (**u**, two-tailed
1383 unpaired t-test: $t_8 = 0.3742$, $P = 0.7180$), ILM-SS tractography (**v**, two-tailed unpaired t-test: $t_8 =$
1384 0.0516 , $P = 0.9601$), ILM-SS tractography (**w**, two-tailed unpaired t-test: $t_8 = 0.4177$, $P = 0.6871$),
1385 ILM-SS tractography (**x**, two-tailed unpaired t-test: $t_8 = 0.9447$, $P = 0.3725$), and ILM-SS
1386 tractography (**y**, two-tailed unpaired t-test: $t_8 = 0.1414$, $P = 0.8911$) in *eCN-DTA* mice compared
1387 to littermate controls (n=5 per genotype).

1388 Abbreviations: CTX=cerebral cortex; OLF=olfactory bulb; HPF=hippocampal formation;
1389 AMY=amygdala; STR=striatum; PAL=pallidum; TH=thalamus; HY=hypothalamus; MB=midbrain;
1390 HB=hindbrain; CB=cerebellum; ILM=intralaminar nuclei; SS=primary somatosensory cortex;
1391 MO=primary motor cortex; DS=dorsal striatum. ns, not significant: $P \geq 0.05$. Data are presented
1392 as mean values \pm SD for **a, j** and mean value \pm SEM for **d,e,k-o,s-y**.




1393

1394 **Supplementary Fig. 1 | *SepW1-Cre* recombines in granule cells and unipolar brush cells.**

1395 **a**, Schematic representation of sagittal plane of an adult mouse showing where **b** and **c** images
1396 were acquired.

1397 **b**, Immunofluorescence images of tdTomato (magenta) and NeuN (green) co-expressing granule
1398 cells in adult *SepW1-Cre; Ai75D* mice. Scale bars = 100 µm; inset scale bars = 25 µm.

1399 **c**, Immunofluorescence images of tdTomato (magenta) and TBR2 (green) co-expressing unipolar
1400 brush cells in adult *SepW1-Cre; Ai75D* mice. Scale bars = 100 µm.



1401

1402 **Supplementary Fig. 2 | Motor coordination during behavior is largely intact after acute**
 1403 **chemogenetic inhibition of adult MedP eCN.**

1404 **a**, Schematic (left) and representative images of mCherry expression (right) in MedA (upper row)
 1405 and MedP (lower row) CN in the five control mice. The other six control mice were Cre-negative
 1406 (treated with CNO). Scale bars = 500 μ m.

1407 **b**, Schematic (left) and representative images of hM4Di-mCherry expression (right) in MedA and
1408 MedP CN in the eleven MedP-hM4Di mice. Scale bars = 500 μ m.

1409 **c**, Distance travelled during basal locomotion by 5 min time bins (n=11 per group). Repeated
1410 measure two-way ANOVA: no main effect of time ($P = 0.0609$), chemogenetics ($P = 0.9730$) or
1411 interaction ($P = 0.9975$).


1412 **d**, Average velocity during basal locomotion by 5 min time bins (n=11 per group). Repeated
1413 measure two-way ANOVA: main effect of time ($F_{4,870,97.41} = 28.43$, $P < 0.0001$), but not of
1414 chemogenetics ($P = 0.7000$) or interaction ($P = 0.8668$).

1415 **e**, Latency to fall on the first trial of the accelerating rotarod test (MedP-hM4Di: n=11, control:
1416 n=10; Mann Whitney U test: $U = 48$, $P = 0.6412$).

1417 **f**, Total distance travelled in the Y-maze (MedP-hM4Di: n=10, control: n=9; two-tailed unpaired t-
1418 test: $t_{17} = 2.648$, $P = 0.0169$).

1419 **g**, Total number of arm entries in the Y-maze (MedP-hM4Di: n=10, control: n=9; Mann Whitney
1420 U test: $U = 30$, $P = 0.2326$).

1421 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1422


1423 **Supplementary Fig. 3 | *SepW1-Cre* recombines in the developing excitatory cerebellar**
1424 **neurons and *SepW1-En1/2* CKOs have preferential loss of MedP CN.**

1425 **a,b,** Schematic (left) and representative images (right) of sagittal sections stained for tdTomato
1426 (magenta) in *SepW1-Cre; Ai75D* mice showing recombination at E14.5 (b) but not at E13.5 (a) in
1427 eCN in the NTZ marked by MEIS2 (green). NTZ = nuclear transitory zone.

1428 **c,** Schematic (left) and representative sagittal image (right) of tdTomato (magenta) expression in
1429 *SepW1-Cre; Ai75D* mice showing recombination at postnatal day (P1) in TBR2+ (green) unipolar
1430 brush cells.

1431 **d**, Schematic (left) and representative sagittal images (right) of tdTomato (magenta) expression
1432 in *SepW1-Cre; Ai75D* mice showing recombination at P7 in p27+ (green) differentiated granule
1433 cells in the internal granule cell layer (IGL), but not in proliferating granule cell precursors in the
1434 external granule cell layer (EGL). Scale bars = 100 μ m; inset scale bars = 20 μ m.

1435 **e**, Representative images of coronal sections stained for NeuN (single channel), NeuN (green)
1436 and tdTomato (magenta) co-labeling in the posterior CN of *SepW1-Cre; Ai75D* and *SepW1-En1/2*
1437 *CKO; Ai75D* mice (*SepW1-Cre/+; En1^{flox/flox}; En2^{flox/flox}; R26^{LSL-nls-tdTomato/+}*). NeuN labeling near the
1438 MedP of mutants are ectopic unipolar brush cells that are not TBR2+ or MEIS2+ (confirmed in
1439 Krishnamurthy et al., 2024). Abbreviations: MedP=Posterior medial; IntP=Posterior interposed.
1440 Scale bars for low magnification = 500 μ m; scale bars for high magnification = 100 μ m.
1441 Scale bars in **a**, **b**, **c** = 250 μ m; inset scale bars = 50 μ m.



1442

1443 **Supplementary Fig. 4 | Motor coordination during behaviors is not altered in *SepW1-En1/2***

1444 **CKOs.**


1445 **a**, Distance travelled during basal locomotion by 5 min time bins (*SepW1-En1/2* CKOs: n=24,
1446 littermate controls: n=27). Repeated measure two-way ANOVA: main effect of time ($F_{5,410,265.1} =$
1447 71.20, $P < 0.0001$), but not of genotype ($P = 0.2081$) or interaction ($P = 0.2042$).

1448 **b**, Average velocity during basal locomotion by 5 min time bins (*SepW1-En1/2* CKOs: n=24,
1449 littermate controls: n=27). Repeated measure two-way ANOVA: main effect of time ($F_{7,996,390.3} =$
1450 2.386, $P = 0.0162$), but not of genotype ($P = 0.3429$) or interaction ($P = 0.1806$).

1451 **c**, Latency to fall on the first trial of the accelerating rotarod test (*SepW1-En1/2* CKOs: n=23,
1452 littermate controls: n=27; Mann-Whitney U test: $U = 240.5$, $P = 0.1759$).

1453 **d**, Total distance travelled in the Y-maze (*SepW1-En1/2* CKOs: n=23, littermate controls: n=26;
1454 Mann-Whitney U test: $U = 266$, $P = 0.5184$).

- 1455 e, Total number of arm entries in the Y-maze (*SepW1-En1/2* CKOs: n=23, littermate controls:
1456 n=26; two-tailed unpaired t-test: $t_{47} = 1.397$, $P = 0.1689$).
1457 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1458

1459 **Supplementary Fig. 5 | Remaining CN neurons in eCN-DTA mice are inhibitory neurons.**

1460 **a,b**, Representative images of coronal sections of triple RNA *in situ* analysis of *Slc32a1*, *Slc17a6*

1461 and *Slc6a5* with single channel expression in anterior (**a**) and posterior (**b**) CN of eCN-DTA mice

1462 and littermate controls. Dotted outlines indicate the CN subregions. Abbreviations: MedA=Anterior

1463 medial; MedP=Posterior medial; IntA=Anterior interposed; IntP=Posterior interposed; Lat=Lateral.


1464 Scale bars = 500 μ m.

1465 **c**, Representative images from the MedA region of double RNA *in situ* hybridization and

1466 immunofluorescence for *Slc6a5* and tdTomato in P30 *Atoh1-tTA; tetO-Cre; Ai75D* (*Atoh1-tTA/+;*

1467 *tetO-Cre; R26^{L^{SL-nls-tdTomato}/+}*) mice treated with doxycycline from E13.5 until P30. *Slc6a5*+ CN
1468 neurons are not labeled by the *Atoh1-tTA* transgene (tdTomato as a readout). Scale bars = 250
1469 um; inset scale bars = 50 um.

1470 **d**, Representative images from the MedA region of double RNA *in situ* hybridization and
1471 immunofluorescence for *Slc6a5* and tdTomato in P30 *Atoh1-Cre; Ai75D* mice. Subset of *Slc6a5*+
1472 CN neurons are labeled by the *Atoh1-Cre* transgene (tdTomato as a readout). Scale bars = 250
1473 um; inset scale bars = 50 um.



1474


1475 **Supplemental Fig. 6 | eCN-DTA mice show reduced growth in the anterior and central**
1476 **vermis.**

1477 **a**, Representative images of H&E labeled vermis in eCN-DTA and littermate control mice. Anterior,
1478 central and posterior sectors (ASec, CSec, and PSec, respectively) are outlined in dotted lines.
1479 Scale bars = 1 mm.

1480 **b**, Quantification of sector area in eCN-DTA mice (n=5) compared to littermate controls (n=6).
1481 Ordinary two-way ANOVA: main effect of genotype ($F_{1,9} = 17.96$, $P = 0.0022$), main effect of sector
1482 ($F_{1,693,15,23} = 264.6$, $P < 0.0001$), and interaction ($F_{2,18} = 10.65$, $P = 0.0009$); with post hoc two-
1483 tailed t-tests with uncorrected Fisher's LSD for effect of genotype for ASec ($t_{8,779} = 3.100$, $P =$
1484 0.0131), CSec ($t_{8,706} = 8.001$, $P < 0.0001$), and PSec ($P = 0.0540$).

1485 ns, not significant: $P \geq 0.05$. Data are presented as mean \pm SEM.

1486



1487

1488 **Supplementary Fig. 7 | Motor coordination during behavior is task-dependent in eCN-DTA**

1489 **mice.**

1490 **a**, Distance travelled during basal locomotion by 5 min time bins (eCN-DTA mice: n=16, littermate

1491 controls: n=15). Repeated measure two-way ANOVA: main effect of time ($F_{5,410,156.9} = 100.4$, $P <$

1492 0.0001), main effect of genotype ($F_{1,29} = 8.210$, $P = 0.0077$), and interaction ($F_{11,319} = 2.629$, $P =$

1493 0.0032); with post hoc two-tailed t-tests with Šídák correction for effect of genotype for 30-35 min
1494 ($t_{20.48} = 3.245$, $P = 0.0466$) but no other comparisons ($P \geq 0.05$).

1495 **b**, Average velocity during basal locomotion by 5 min time bins (*eCN-DTA* mice: n=16, littermate
1496 controls: n=15). Repeated measure two-way ANOVA: main effect of time ($F_{5,283,153.2} = 5.057$, $P =$
1497 0.0002), but not of genotype ($P = 0.0883$) or interaction ($P = 0.0589$).

1498 **c**, Latency to fall on the first trial of the accelerating rotarod test (*eCN-DTA* mice: n=16, littermate
1499 controls: n=14; Mann-Whitney *U* test: $U = 72.50$, $P = 0.1034$).

1500 **d**, Average swimming velocity during a three-minute swim (*eCN-DTA* mice: n=16, littermate
1501 controls: n=15). Repeated measure two-way ANOVA: main effect of time ($F_{5,145} = 137.8$, $P <$
1502 0.0001), but not of genotype ($P = 0.3829$) or interaction ($P = 0.9235$).

1503 **e**, Total distance travelled during the Y-maze test (*eCN-DTA* mice: n=15, littermate controls: n=14;
1504 two-tailed unpaired t-test: $t_{27} = 3.027$, $P = 0.0054$).

1505 **f**, Total number of arm entries in the Y-maze (*eCN-DTA* mice: n=15, littermate controls: n=14;
1506 two-tailed unpaired t-test: $t_{27} = 2.969$, $P = 0.0062$).

1507 **g**, Average total distance travelled during two days of testing in the plus-maze (*eCN-DTA* mice:
1508 n=16, littermate controls: n=15: two-tailed unpaired t-test: $t_{29} = 2.211$, $P = 0.0350$).

1509 **h**, Average total number of entries during two days of testing in the plus-maze (*eCN-DTA* mice:
1510 n=16, littermate controls: n=15: two-tailed unpaired t-test: $t_{29} = 2.114$, $P = 0.0432$).

1511 **i**, Total time in which the animal's nose was within the contact zone of a novel mouse (NM) and
1512 novel object (NO) during the three-chambered social approach test (*eCN-DTA* mice: n=16,
1513 littermate controls: n=15). Repeated measure two-way ANOVA: main effect of location ($F_{1,29} =$
1514 53.64 , $P < 0.0001$), but not of genotype ($P = 0.5828$) or interaction ($P=0.4639$); with post hoc two-
1515 tailed t-tests with Šídák correction for effect of location for littermate controls ($t_{29} = 5.614$, $P <$
1516 0.0001) and *eCN-DTA* mice ($t_{29} = 4.731$, $P = 0.0001$) mice.


1517 **j**, Total distance travelled during habituation and test phases of the three-chambered social
1518 approach test (*eCN-DTA* mice: n=16, littermate controls: n=15). Repeated measure two-way

1519 ANOVA: main effect of phase ($F_{1,29} = 358.9$, $P < 0.0001$), genotype ($F_{1,29} = 7.130$, $P = 0.0123$),
1520 and interaction ($F_{1,29} = 5.461$, $P = 0.0266$); with post hoc two-tailed t-tests with Šídák correction
1521 for effect of genotype for the habituation phase ($t_{58} = 3.433$, $P = 0.0022$) but not test phase ($t_{58} =$
1522 1.344 , $P = 0.3343$).

1523 **k**, Total time spent in the open arms of an elevated plus maze (*eCN-DTA* mice: $n=14$, littermate
1524 controls: $n=14$; two-tailed unpaired t-test: $t_{26} = 1.662$, $P = 0.1086$).

1525 **l**, Total distance travelled in an elevated plus maze (*eCN-DTA* mice: $n=15$, littermate controls:
1526 $n=16$; two-tailed unpaired t-test: $t_{29} = 2.320$, $P = 0.0276$).

1527 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1528

1529 **Supplementary Fig. 8 | Inhibitory CN neurons are significantly reduced across the**
 1530 **mediolateral axis in *Atoh1-En1/2* CKOs.**

1531 **a,b**, Representative images of immunofluorescent staining NeuN (single channel) and NeuN

1532 (green), tdTomato (magenta) co-labeling in of coronal sections of the anterior (**a**) and posterior


1533 (b) CN of *Atoh1-Cre; Ai75D* and *Atoh1-En1/2* CKO; *Ai75D* mice. Abbreviations: MedA=Anterior
1534 medial; MedP=Posterior medial; IntA=Anterior interposed; IntP=Posterior interposed; Lat=Lateral.
1535 Scale bars = 500 um, scale bars for **i-iv** = 100 um.

1536 c, Experimental design for quantifying excitatory and inhibitory CN neurons in *Atoh1-Cre; Ai75D*
1537 (*Atoh1-Cre/+; R26^{LSL-nls-tdTomato/+}*) and *Atoh1-En1/2* CKO; *Ai75D* (*Atoh1-Cre/+; En1^{flox/flox}; En2^{flox/flox}; R26^{LSL-nls-tdTomato/+}*) mice.

1539 d, Quantification and distribution of excitatory CN neurons in half of the cerebellum (every second
1540 section). Two-way ANOVA: main effect of % mediolateral distance ($F_{19,120} = 31.38$, $P < 0.0001$),
1541 genotype ($F_{1,120} = 400.1$, $P < 0.0001$), and interaction ($F_{19,120} = 8.830$, $P < 0.0001$); with post hoc
1542 two-tailed t-tests with uncorrected Fisher's LSD for effect of genotype for bin 10-80% (list of t
1543 value for each bin: $t_{120} = 4.029, 7.169, 8.828, 7.267, 6.726, 6.087, 7.103, 4.759, 5.516, 5.122,$
1544 $7.85, 5.06, 6, 4.169$; all P values: $P < 0.0001$), for bins 80-85% ($t_{120} = 3.435$, $P = 0.0008$), and no
1545 other comparisons ($P \geq 0.05$). Abbreviations: Med=medial; Int=interposed; Lat=lateral.

1546 e, Quantification and distribution of inhibitory CN neurons in half of the cerebellum (every second
1547 section). Two-way ANOVA: main effect of % mediolateral distance ($F_{19,120} = 23.97$, $P < 0.0001$),
1548 and genotype ($F_{1,120} = 50.81$, $P < 0.0001$), but not interaction ($F_{19,120} = 1.659$, $P = 0.0531$); with
1549 post hoc two-tailed t-tests with uncorrected Fisher's LSD for effect of genotype for bin 20-25%
1550 ($t_{120} = 2.094$, $P = 0.0384$), bin 55-60% ($t_{120} = 2.141$, $P = 0.0343$), bin 60-65% ($t_{120} = 4.114$, $P <$
1551 0.0001), bin 80-85% ($t_{120} = 5.316$, $P < 0.0001$), and no other comparisons ($P \geq 0.05$). Abbreviations:
1552 Med=medial; Int=interposed; Lat=lateral.

1553 Data are presented as mean values \pm SEM.



1554

1555 **Supplementary Fig. 9 | Motor coordination during behavior is task-dependent in *Atoh1-***
 1556 ***En1/2* CKOs.**

1557 **a**, Distance travelled during basal locomotion by 5 min time bins (*Atoh1-En1/2* CKOs: n=33,
 1558 littermate controls: n=35). Repeated measure two-way ANOVA: main effect of time ($F_{7,310,482.5} =$
 1559 171.0, $P < 0.0001$), genotype ($F_{1,66} = 15.45$, $P = 0.0002$), and interaction ($F_{11,726} = 3.120$, $P =$
 1560 0.0004); with post hoc two-tailed t-tests with Šídák correction for effect of genotype on 0-5 min

1561 ($t_{65.21} = 6.250$, $P < 0.0001$), 15-20 min ($t_{61.20} = 3.012$, $P = 0.0443$), 20-25 min ($t_{59.87} = 3.358$, $P =$
1562 0.0163), 50-55 min ($t_{60.88} = 3.556$, $P = 0.0088$), and no other comparisons ($P \geq 0.05$).

1563 **b**, Average velocity during basal locomotion by 5 min time bins (*Atoh1-En1/2* CKOs: $n=33$,
1564 littermate controls: $n=35$). Repeated measure two-way ANOVA: main effect of time ($F_{2,435,160.7} =$
1565 171.0 , $P < 0.0001$), genotype ($F_{1,66} = 57.43$, $P = 0.0002$), and interaction ($F_{11,726} = 4.381$, $P <$
1566 0.0001); with post hoc two-tailed t-tests with Šídák correction for effect of genotype on 0-5 min
1567 ($t_{65.45} = 4.355$, $P = 0.0006$) and 5-60 min (t value for each bin: $t_{65.45} = 4.355$, $t_{61} = 5.693$, $t_{63.58} =$
1568 5.927 , $t_{62.8} = 5.916$, $t_{63.54} = 6.755$, $t_{61.95} = 7.332$, $t_{62.74} = 7.867$, $t_{65.1} = 7.819$, $t_{65.56} = 7.863$, $t_{65.83} =$
1569 7.695 , $t_{66} = 7.698$, $t_{65.53} = 7.589$, all P values: $P < 0.0001$).

1570 **c**, Latency to fall on the first trial of the accelerating rotarod test (*Atoh1-En1/2* CKOs: $n=32$,
1571 littermate controls: $n=30$; Mann-Whitney *U* test: $U = 417$, $P = 0.3792$).

1572 **d**, Average swimming velocity during a three-minute swim (*Atoh1-En1/2* CKOs: $n=35$, littermate
1573 controls: $n=31$). Repeated measure two-way ANOVA: main effect of time ($F_{5,320} = 0.5563$, $P <$
1574 0.0001), but not of genotype ($P = 0.1350$) and interaction ($P = 0.7335$).

1575 **e**, Total distance travelled during the Y-maze ($n=35$ per genotype; Mann-Whitney *U* test: $U = 405$,
1576 $P = 0.0144$).

1577 **f**, Total number of arm entries in the Y-maze ($n=35$ per genotype; two-tailed unpaired t-test: $t_{68} =$
1578 2.548 , $P = 0.0131$).

1579 **g**, Average total distance travelled during two days of testing in the plus-maze ($n=27$ per genotype;
1580 Mann-Whitney *U* test: $U = 332.5$, $P = 0.5857$).

1581 **h**, Average total number of arm entries during two days of testing in the plus-maze ($n=27$ per
1582 genotype; two-tailed unpaired t-test: $t_{52} = 1.839$, $P = 0.0717$).

1583 **i**, Total time in which the animal's nose was within the contact zone of a novel mouse (NM) and
1584 novel object (NO) during the three-chamber social approach test (*Atoh1-En1/2* CKOs: $n=38$,
1585 littermate controls: $n=40$). Repeated measure two-way ANOVA: main effect of location ($F_{1,152} =$
1586 81.64 , $P < 0.0001$), but not of genotype ($P = 0.6191$) or interaction ($P = 0.4360$); with post hoc


1587 two-tailed t-tests with Šídák correction for effect of location for *Atoh1-En1/2* CKOs ($t_{152} = 6.854$,
1588 $P < 0.0001$) and littermate controls ($t_{152} = 5.913$, $P < 0.0001$).

1589 **j**, Total distance travelled during habituation and test phases in the three-chamber social
1590 approach test (*Atoh1-En1/2* CKOs: $n=38$, littermate controls: $n=40$). Repeated measure two-way
1591 ANOVA: main effect of phase ($F_{1,76} = 487.6$, $P < 0.0001$), genotype ($F_{1,76} = 22.58$, $P < 0.0001$),
1592 and interaction ($F_{1,76} = 10.31$, $P = 0.0019$); with post hoc two-tailed t-tests with Šídák correction
1593 for effect of genotype for the habituation phase ($t_{152} = 5.772$, $P < 0.0001$) and test phase ($t_{152} =$
1594 2.491 , $P = 0.0275$).

1595 **k**, Total time spent in the open arms of the elevated plus maze ($n=50$ per genotype; Mann-Whitney
1596 U test: $U = 878$, $P = 0.01$).

1597 **l**, Total distance travelled in the elevated plus maze ($n=50$ per genotype; Mann-Whitney U test: U
1598 $= 467$, $P = 0.2705$).

1599 ns, not significant: $P \geq 0.05$. Data are presented as mean values \pm SEM.



1600

1601 **Supplementary Fig. 10 | Brain volume and connectivity changes in *Atoh1-En1/2* CKO and**

1602 ***eCN-DTA* mice.**

1603 **a**, Quantification of regional brain volumes in *Atoh1-En1/2* CKOs (n=12) compared to littermate

1604 controls (n=13). Two-tailed unpaired t-tests to test for effect of genotype on CTX ($t_{23} = 3.633$, $P =$

1605 0.0014), HPF ($t_{23} = 2.329$, $P = 0.03$), STR ($t_{23} = 2.612$, $P = 0.016$), PAL ($t_{23} = 3.143$, $P = 0.005$),

1606 TH ($t_{23} = 3.052$, $P = 0.006$), MB ($t_{23} = 5.665$, $P < 0.0001$), HB ($t_{23} = 11.16$, $P < 0.0001$), CB ($t_{23} =$
1607 11.15 , $P < 0.0001$), other comparisons $P \geq 0.05$.

1608 **b**, Quantification of whole brain volume in *Atoh1-En1/2* CKOs compared to littermate controls
1609 (*Atoh1-En1/2* CKOs: $n=12$, littermate controls: $n=13$; two-tailed unpaired t-test: $t_{23} = 4.298$, $P =$
1610 0.0003).

1611 **c**, Quantification of forebrain and midbrain combined volume in *Atoh1-En1/2* CKOs compared to
1612 littermate controls (*Atoh1-En1/2* CKOs: $n=12$, littermate controls: $n=13$; two-tailed unpaired t-test:
1613 $t_{23} = 2.087$, $P = 0.0481$).

1614 **d**, Quantification of average (left and right hemispheres) ACA-AMY tractography in *Atoh1-En1/2*
1615 CKOs compared to littermate controls (*Atoh1-En1/2* CKOs: $n=12$, littermate controls: $n=13$; two-
1616 tailed unpaired t-test: $t_{23} = 14.35$, $P < 0.0001$).

1617 **e**, Quantification of average (left and right hemispheres) SS-AMY tractography in *Atoh1-En1/2*
1618 CKOs compared to littermate controls (*Atoh1-En1/2* CKOs: $n=12$, littermate controls: $n=13$; Mann-
1619 Whitney U test: $U = 0$, $P < 0.0001$).

1620 **f**, Quantification of average (left and right hemispheres) HPF-TH tractography in *Atoh1-En1/2*
1621 CKOs compared to littermate controls (*Atoh1-En1/2* CKOs: $n=12$, littermate controls: $n=13$; two-
1622 tailed unpaired t-test: $t_{23} = 4.298$, $P = 0.0003$).

1623 **g**, Quantification of TH-CN tractography in *Atoh1-En1/2* CKOs ($n=12$) compared to littermate
1624 controls ($n=13$). Ordinary two-way ANOVA: main effect of genotype ($F_{1,46} = 166.5$, $P < 0.0001$),
1625 but not of hemisphere ($P = 0.3838$) or interaction ($P = 0.8437$); with post hoc two-tailed t-tests
1626 with uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{46} = 9.265$, $P < 0.0001$)
1627 and right hemisphere ($t_{46} = 8.985$, $P < 0.0001$).

1628 **h**, Quantification of ILM-SS tractography in *Atoh1-En1/2* CKOs ($n=12$) compared to littermate
1629 controls ($n=13$). Ordinary two-way ANOVA: main effect of genotype ($F_{1,46} = 18.16$, $P < 0.0001$),
1630 but not of hemisphere ($P = 0.1675$) or interaction ($P = 0.9536$); with post hoc two-tailed t-tests

1631 with uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{46} = 3.055$, $P = 0.0037$)
1632 and right hemisphere ($t_{46} = 2.972$, $P = 0.0047$).

1633 **i**, Quantification of ILM-MO tractography in *Atoh1-En1/2* CKOs (n=12) compared to littermate
1634 controls (n=13). Ordinary two-way ANOVA: main effect of genotype ($F_{1,46} = 5.585$, $P = 0.024$), but
1635 not of hemisphere ($P = 0.3553$) or interaction ($P = 0.8322$); with post hoc two-tailed t-tests with
1636 uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{46} = 1.822$, $P = 0.0750$) and
1637 right hemisphere ($t_{46} = 1.520$, $P = 0.1353$).

1638 **j**, Quantification of ILM-DS tractography in *Atoh1-En1/2* CKOs (n=12) compared to littermate
1639 controls (n=13). Ordinary two-way ANOVA: main effect of genotype ($F_{1,46} = 11.94$, $P < 0.0001$)
1640 and hemisphere ($F_{1,46} = 29.03$, $P < 0.0001$), but not of interaction ($P = 0.9007$); with post hoc two-
1641 tailed t-tests with uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{46} = 3.055$,
1642 $P = 0.0037$) and right hemisphere ($t_{46} = 2.972$, $P = 0.0047$).

1643 **k**, Quantification of SS-DS tractography in *Atoh1-En1/2* CKOs (n=12) compared to littermate
1644 controls (n=13). Ordinary two-way ANOVA: main effect of genotype ($F_{1,46} = 32.43$, $P < 0.0001$),
1645 but not of hemisphere ($P = 0.0662$) or interaction ($P = 0.7773$); with post hoc two-tailed t-tests
1646 with uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{46} = 4.228$, $P = 0.0001$)
1647 and right hemisphere ($t_{46} = 3.825$, $P = 0.0004$).

1648 **l**, Quantification of MO-SS tractography in *Atoh1-En1/2* CKOs (n=12) compared to littermate
1649 controls (n=13). Ordinary two-way ANOVA: main effect of genotype ($F_{1,46} = 10.60$, $P = 0.0021$),
1650 but not of hemisphere ($P = 0.0535$) or interaction ($P = 0.4680$); with post hoc two-tailed t-tests
1651 with uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{46} = 2.820$, $P = 0.0071$)
1652 and right hemisphere ($t_{46} = 1.785$, $P = 0.0809$).

1653 **m**, Quantification of regional brain volumes in *eCN-DTA* mice (n=5) compared to littermate
1654 controls (n=5). Two-tailed unpaired t-tests to test for effect of genotype on MB ($t_8 = 4.935$, $P =$
1655 0.001) and CB ($t_8 = 3.130$, $P = 0.014$), other comparisons $P \geq 0.05$.

1656 **n**, Quantification of whole brain volume in *eCN-DTA* mice compared to littermate controls (n=5
1657 per genotype; two-tailed unpaired t-test: $t_8 = 6.346$, $P = 0.0002$).

1658 **o**, Quantification of forebrain and midbrain combined volumes in *eCN-DTA* mice compared to
1659 littermate controls (n=5 per genotype; two-tailed unpaired t-test: $t_8 = 3.055$, $P = 0.0157$).

1660 **p**, Quantification of average (left plus right hemispheres) ACA-SS tractography in *eCN-DTA* mice
1661 compared to littermate controls (n=5 per genotype; two-tailed unpaired t-test: $t_8 = 7.743$, $P <$
1662 0.0001).

1663 **q**, Quantification of average (left plus right hemispheres) HPF-STR tractography in *eCN-DTA*
1664 mice compared to littermate controls (n=5 per genotype; two-tailed unpaired t-test: $t_8 = 6.324$, P
1665 $= 0.0002$).

1666 **r**, Quantification of TH-CN tractography in *eCN-DTA* mice (n=5) compared to littermate controls
1667 (n=5). Ordinary two-way ANOVA: main effect of genotype ($F_{1,16} = 37.89$, $P < 0.0001$), but not of
1668 hemisphere ($P = 0.9717$) or interaction ($P = 0.7233$); with post hoc two-tailed t-tests with
1669 uncorrected Fisher's LSD for effect of genotype for left hemisphere ($t_{16} = 4.103$, $P = 0.0008$) and
1670 right hemisphere ($t_{16} = 4.613$, $P = 0.0003$).

1671 **s**, Quantification of ILM-SS tractography in *eCN-DTA* mice (n=5) compared to littermate controls
1672 (n=5). Ordinary two-way ANOVA: no main effect of genotype ($P = 0.6080$), hemisphere ($P =$
1673 0.9875) or interaction ($P = 0.8883$).

1674 **t**, Quantification of ILM-MO tractography in *eCN-DTA* mice (n=5) compared to littermate controls
1675 (n=5). Ordinary two-way ANOVA: no main effect of genotype ($P = 0.9440$), hemisphere ($P =$
1676 0.9600) or interaction ($P = 0.8281$).

1677 **u**, Quantification of ILM-DS tractography in *eCN-DTA* mice (n=5) compared to littermate controls
1678 (n=5). Ordinary two-way ANOVA: no main effect of genotype ($P = 0.6155$), hemisphere ($P =$
1679 0.5876) or interaction ($P = 0.4505$).

1680 **v**, Quantification of SS-DS tractography in *eCN-DTA* mice (n=5) compared to littermate controls
1681 (n=5). Ordinary two-way ANOVA: no main effect of genotype (P = 0.2886), hemisphere (P =
1682 0.8391) or interaction (P = 0.5482).

1683 **w**, Quantification of MO-SS tractography in *eCN-DTA* mice (n=5) compared to littermate controls
1684 (n=5). Ordinary two-way ANOVA: no main effect of genotype (P = 0.8636), hemisphere (P =
1685 0.1664) or interaction (P = 0.1924).

1686 Abbreviations: CTX=cerebral cortex; OLF=olfactory bulb; HPF=hippocampal formation;
1687 AMY=amygdala; STR=striatum; PAL=pallidum; TH=thalamus; HY=hypothalamus; MB=midbrain;
1688 HB=hindbrain; CB=cerebellum; ILM=intralaminar nuclei; SS=primary somatosensory cortex;
1689 MO=primary motor cortex; ACA = anterior cingulate cortex. ns, not significant: $P \geq 0.05$. Data are
1690 presented as mean values \pm SD for **a,b,g,h** and mean value \pm SEM for **c-f,i-k**.

eCN phenotype & behavior	MedP-hM4Di	<i>SepW1-En1/2</i> CKOs	<i>Atoh1-En1/2</i> CKOs	eCN-DTA
eCN phenotype	MedP eCN inhibited	MedP eCN gone MedA eCN reduced 50%	MedP & IntP eCN gone MedA & IntA eCN reduced 50%	All eCN gone
Negative geotaxis P7 & P11	NA	P	X	X
Righting reflex P7	NA	P	P	X
Footprint	P	P	X	X
Basal locomotion	P	P	X	X
Accelerating rotarod	P	P	X	P
Water Y maze	reversal	P	Initial & reversal	P
Y-maze	P	P	X	P
Plus-maze	NA	NA	X	P
Social Preference	NA	NA	P	P
Elevated Plus Maze	NA	NA	P	P
Grooming	NA	NA	P	P
Diffusion MRI	NA	NA	Increased connectivity thalamo-cortical-striatal	No change
Compensation	NA	From remaining eCN and/or extracerebellar circuits	Extracerebellar circuits interfere with non-motor behaviors	From extracerebellar circuits

1691

1692 **Supplementary Fig. 11 | Summary of results.**

1693 Legend: ✓ = no difference; NA = not applicable; X = impairment.

1694 **Table. 1 | Key resources and sources.**

REAGENT OR RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-NeuN (A60)	Millipore Sigma	Catalog No: MAB377
Guinea pig polyclonal anti-NeuN	Millipore Sigma	Catalog No: ABN90
Rabbit anti-Calbindin D-28k	Swant Inc	Catalog No: CD38
Guinea pig polyclonal anti-Parvalbumin	Synaptic Systems	Catalog No: 195 044
Chicken polyclonal anti-RFP	Rockland Immunochemicals	Catalog No: 600-901-379
Mouse monoclonal anti-MEIS2 (H-10)	Santa Cruz Biotechnology	Catalog No: sc-515470
Rabbit polyclonal anti-TBR2	Abcam	Catalog No: ab23345
Rabbit anti-p27	BD Biosciences	Catalog No: 610241
Goat Alexa Fluor 555 anti-chicken IgY (H+L)	Invitrogen	Catalog No: A21437
Donkey Alexa Fluor 488 anti-rabbit IgG (H+L)	Invitrogen	Catalog No: A21206
Donkey Alexa Fluor 647 anti-rabbit IgG (H+L)	Invitrogen	Catalog No: A31573
Donkey Alexa Fluor 488 anti-mouse IgG (H+L)	Invitrogen	Catalog No: A21202
Donkey Alexa Fluor 647 anti-mouse IgG (H+L)	Invitrogen	Catalog No: A31571
Donkey Alexa Fluor 647 anti-guinea pig IgG (H+L)	Invitrogen	Catalog No: A21450
Goat anti-mouse IgG antibody (H+L), Biotinylated	Vector Laboratories	Catalog No: BA-9200
Goat anti-chicken IgG antibody (H+L), Biotinylated	Vector Laboratories	Catalog No: BA-9010
Virus strains		
AAV2-hSyn-mCherry (titer: 2.6×10^{13} GC/mL)	Addgene	Catalog No: 114472-AAV2 (Lot No: v53550)
AAV2-hSyn-DIO-mCherry (titer: 2.1×10^{13} GC/mL)	Addgene	Catalog No: 50459-AAV2 (Lot No: v122065)
AAV2-hSyn-DIO-hM4Di-mCherry (titer: 2.3×10^{13} GC/mL)	Addgene	Catalog No: 44362-AAV2 (Lot No: v117556)
Chemicals		
32% paraformaldehyde	Electron Microscopy Sciences	Catalog No: 15714
Hematoxylin 2	Richard-Allan Scientific	Catalog No: 7231
Eosin-Y	Richard-Allan Scientific	Catalog No: 7111
Bluing reagent	Richard-Allan Scientific	Catalog No: 7301
Clarifier 2	Richard-Allan Scientific	Catalog No: 7402
Gadodiamide	Millipore Sigma	Catalog No: 131410-48-5
Hoechst 33258, Pentahydrate (bis-Benzimide)	Invitrogen	Catalog No: H3569
Dextran, Tetramethylrhodamine, 10,000 MW, Lysine Fixable (Fluoro-Ruby)	Thermo-Fisher Scientific	Catalog No: D1817
Dextran, Biotin, 10,000 MW, Lysine Fixable (BDA-10K)	Thermo-Fisher Scientific	Catalog No: D1956
Doxycycline hyclate	Sigma Aldrich	Catalog No: D9891
VECTASTAIN Elite ABC-HRP Kit, Peroxidase (Standard)	Vector Laboratories	Catalog No: PK-6100
3,3'-Diaminobenzidine tetrahydrochloride (DAB)	Sigma Aldrich	Catalog No: D5905
Fluoro-Gel	Electron Microscopy Sciences	Catalog No: 17985-10

Fluoromount-G	ThermoFisher Scientific	Catalog No: 00-4958-02
Heparin sodium salt	Sigma Aldrich	Catalog No: H3393-50KU
UltraPure DNase/RNase-Free Distilled Water	ThermoFisher Scientific	Catalog No: 10977023
Phosphate-Buffered Saline (10X) pH 7.4, RNase-free	ThermoFisher Scientific	Catalog No: AM9624
Clozapine N-oxide	Enzo Life Sciences	Catalog No: BML-NS105-0025
Critical commercial assays		
RNAscope Multiplex Fluorescent Detection Kit v2	Advanced Cell Diagnostics	Catalog No: 323110
RNAscope Target Retrieval Reagents	Advanced Cell Diagnostics	Catalog No: 322000
RNAscope Protease III	Advanced Cell Diagnostics	Catalog No: 322337
RNAscope LS Multiplex TSA Buffer Pack	Advanced Cell Diagnostics	Catalog No: 322810
Mm-Slc32a1-C1	Advanced Cell Diagnostics	Catalog No: 319191
Mm-Slc17a6-E2-C2	Advanced Cell Diagnostics	Catalog No: 428871-C2
Mm-Slc6a5-C3	Advanced Cell Diagnostics	Catalog No: 409741-C3
TSA Vivid fluorophore 520	Advanced Cell Diagnostics	Catalog No: 323271
TSA Vivid fluorophore 570	Advanced Cell Diagnostics	Catalog No: 323272
TSA Vivid fluorophore 650	Advanced Cell Diagnostics	Catalog No: 323273
Experimental Models: Organisms/Strains		
Mouse: Swiss Webster	Taconic Biosciences	Stock No: SW
Mouse: <i>Atoh1-Cre; B6.Cg-Tg(Atoh1-Cre)1Bfri/J</i>	The Jackson Laboratory; Materi et al., 2005	Stock No: 011104
Mouse: <i>SepW1-Cre; B6.FVB(Cg)-Tg(Selenow-cre)NP39Gsatt/Mmucl</i>	Mutant Mouse Resource & Research Centers (MMRRC); Gerfen, Paletzki & Heintz, 2013	037622-UCD (mice generously provided by N. De Marco Lab, Weill Cornell Medicine)
Mouse: <i>tetO-Cre; B6.Cg-Tg(TetO-cre)1Jaw/J</i>	The Jackson Laboratory	Stock No: 006234
Mouse: 129S1/SvImJ	The Jackson Laboratory	Stock No: 002448
Mouse: <i>En1^{Cre}; En1^{tm2(cre)Wrst/J}</i>	The Jackson Laboratory; Kimmel et al. 2000	Stock No: 007916
Mouse: <i>Atoh1-tTA</i>	Willett et al., 2019	N/A
Mouse: <i>Igs7^{TRE-lox-tdTomato-STOP-lox-DTA*G128D} (Cre- and tTA- dependent DTA; Igs7^{DRAGON-DTA} in manuscript; DRAGON = Doxycycline-controlled and Recombinase Activated Gene Overexpression); Igs7^{tm2(tetO-tdTomato, -DTA*G128D)Rdiez/AljJ}</i>	The Jackson Laboratory; Ahmadzadeh et al., 2020	Stock No: 034778
Mouse: Ai75D (Cre-dependent nuclear tdTomato reporter, Ai75 in manuscript): <i>B6.Cg-Gt(ROSA)26Sor^{tm75.1(CAG-tdTomato*)Hze/J}</i>	The Jackson Laboratory; Daigle et al., 2018	Stock No: 025106
Mouse: <i>En1^{flox}; En1^{tm8.1Alj/J}</i>	The Jackson Laboratory; Sgaier et al., 2007	Stock No: 007918
Mouse: <i>En2^{flox}; En2^{tm6Alj/J}</i>	The Jackson Laboratory; Cheng et al., 2010	Stock No: 008872
Mouse: <i>En1^{flox/flox}; En2^{flox/flox} (littermate control in manuscript)</i>	Willett et al., 2019	N/A (generated with 007918 and 008872 in-house)
Mouse: <i>Atoh1-Cre/+; En1^{flox/flox}; En2^{flox/flox} (Atoh1-En1/2 CKOs in manuscript)</i>	Willett et al., 2019	N/A (generated with 007918, 008872, and 011104 in-house)

Mouse: <i>SepW1-Cre/+; En1^{flox/flox};</i> <i>En2^{flox/flox}</i> (SepW1-En1/2 CKOs in manuscript)	This manuscript	N/A (generated with 007918, 008872 in-house)
Mouse: <i>Atoh1-tTA/+; En1^{Cre/+};</i> <i>Igs7^{DRAGON-DTA/+}</i> (eCN-DTA in manuscript)	This manuscript; Ahmadzadeh et al., 2020	N/A (generated with <i>Atoh1-tTA</i> , 007916, and 034778 in-house)
Software		
Fiji	ImageJ/Fiji	https://fiji.sc/
Prism8	GraphPad	https://www.graphpad.com/scientific-software/prism/
ANY-maze	Stoelting Co	https://www.anymaze.co.uk/index.htm
BORIS	University of Torino	https://www.boris.unito.it
AMIRA	ThermoFisher Scientific	
DTIStudio	Jiang et al., 2006	https://mrstudios.org
MRtrix	Wu and Zhang (2016)	https://www.mrtrix.org/
MATLAB R2022b	MathWorks	https://www.mathworks.com

1696 **Table. 2 | Primers and PCR conditions used for genotyping.**

Allele	Primer sequence (5' to 3')
<i>Atoh1-Cre, En1^{Cre}</i>	GATATCTCACGTA CTGACGG TGACCAGAGTCATCCTTAGC
<i>SepW1-Cre</i>	ACTTGGTTTTGCTCTGACTCGTGAGG CGGCAAACGGACAGAAGCATT
<i>Atoh1-tTA</i>	GTACTGGCACGTGAAGAACAAGCG GCTACTTGATGCTCCTGATCCTCC
<i>Igs7^{DRAGON-WT}</i>	CCCAACGGTCACTTACTTCC CACACCTTTAATCCCGATGC
<i>Igs7^{DRAGON-DTA}</i>	CCCAACGGTCACTTACTTCC GGTAACCGCGGCATAAAAC
<i>En1^{lox}</i>	GCTTGTTTTGGTTTTCCGAGTC GGGCAGAGTAAGCCTTGAGA
<i>En2^{lox}</i>	GAAGGTCTCAAGTTTTAGCCGGTAGCC CCCCTTCCTCCTACATAGTTGGCAGTG
<i>Ai75D</i>	CTGTTCCCTGTACGGCATGG GGCATTAAAGCAGCGTATCC
*For allele specific primers, refer to allele reference.	

1697

1698 **Table 3 | Details of dye and viruses used in stereotaxic surgeries.**

Tracer/virus	Serotype	Company	Catalog no.	Concentration/titer	Stereotaxic coordinate (distance from Bregma)	Injection volume
Dextran, Tetramethylrhodamine, 10,000 MW, Lysine Fixable (Fluoro-Ruby)	n/a	Thermo-Fisher Scientific	D1817	10%	CL: AP, -1.20 mm; ML, 0.69 mm; DV, -3.8 mm PF: AP, -2.1 mm; ML, 0.6 mm; DV, -3.5 mm	CL: 300 nL PF: 100 nL
Dextran, Biotin, 10,000 MW, Lysine Fixable (BDA-10K)	n/a	Thermo-Fisher Scientific	D1956	10%	IntA: AP, -6.24 mm; ML, 1.10 mm; DV, -3.80 mm	300 nL
pAAV-hSyn-mCherry	AAV2	Addgene	114472-AAV2 (Lot No: v53550)	2.6×10^{13} GC/mL	MedA: AP, -6.24 mm; ML, 0.85 mm; DV, -3.70	200 nL
pAAV-hSyn-DIO-mCherry	AAV2	Addgene	50459-AAV2 (Lot No: v122065)	2.1×10^{13} GC/mL	MedP: AP, -6.7 mm; ML, ± 0.9 mm; DV, -3.20	300 nl
pAAV-hSyn-DIO-hM4Di-mCherry	AAV2	Addgene	44362-AAV2 (Lot No: v117556)	2.3×10^{13} GC/mL	MedP: AP, -6.7 mm; ML, ± 0.9 mm; DV, -3.20	300 nl

1699

1700 **Table. 4 | Details of antibodies used for immunofluorescence.**

Antibody (clone)	Species	Company	Catalog no.	IHC	Antigen retrieval	Temperature	Time
Anti-NeuN (A60)	Mouse mono	Millipore Sigma	MAB377	1:1000	20 m	4°C	o/n
Anti-NeuN	Guinea pig poly	Millipore Sigma	ABN90	1:1000	20 m	4°C	o/n
Anti-Calbindin D-28k	Rabbit	Swant Inc	CD38	1:1000	20 m	4°C	o/n
Anti-Parvalbumin	Guinea pig poly	Synaptic Systems	195 044	1:1000	20 m	4°C	o/n
Anti-RFP	Chicken poly	Rockland Immunochemicals	600-901-379	1:1000 (no antigen retrieval) 1:500 (with antigen retrieval)	No 20 m	4°C	o/n or 48 h*
Anti-MEIS2 (H-10)	Mouse mono	Santa Cruz Biotechnology	sc-515470	1:1000	20 m	4°C	o/n or 48 h*
Anti-TBR2	Rabbit poly	Abcam	ab23345	1:500	20 m	4°C	o/n
Anti-p27	Mouse	BD Biosciences	610241	1:500	20 m	4°C	o/n
Alexa Fluor 555 anti-chicken IgY (H+L)	Goat	Invitrogen	A21437	1:500	n/a	RT	1 h
Alexa Fluor 488 anti-rabbit IgG (H+L)	Donkey	Invitrogen	A21206	1:500	n/a	RT	1 h
Alexa Fluor 647 anti-rabbit IgG (H+L)	Donkey	Invitrogen	A31573	1:500	n/a	RT	1 h or 2 h*
Alexa Fluor 488 anti-mouse IgG (H+L)	Donkey	Invitrogen	A21202	1:500	n/a	RT	1 h
Alexa Fluor 647 anti-mouse IgG (H+L)	Donkey	Invitrogen	A31571	1:500	n/a	RT	1 h or 2 h*
Alexa Fluor 647 anti-guinea pig IgG (H+L)	Goat	Invitrogen	A21450	1:500	n/a	RT	1 h
Anti-mouse IgG antibody (H+L), Biotinylated	Goat	Vector Laboratories	BA-9200	1:500	n/a	RT	1 h
Anti-chicken IgG antibody (H+L), Biotinylated	Goat	Vector Laboratories	BA-9010	1:500	n/a	RT	1 h
*Applicable for free-floating immunofluorescence or immunohistochemistry							

1701